

CITATION REPORT

List of articles citing

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

DOI: 10.1021/bi00069a001
Biochemistry, 1993, 32, 4693-7.

Source: <https://exaly.com/paper-pdf/24214681/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1804	Pharmaceutical applications. 1993 , 4, 785-817		
1803	Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. 1993 , 73, 1055-8		1937
1802	An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. 1994 , 264, 1336-40		1377
1801	Enhanced aggregation and beta structure of amyloid beta peptide after coinubation with C1q. 1994 , 39, 448-56		68
1800	Transgenic mouse brain histopathology resembles early Alzheimer's disease. 1994 , 35, 598-607		122
1799	Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. 1994 , 36, 903-11		101
1798	The role of beta-amyloid peptide in Alzheimer's disease. 1994 , 9, 3-31		6
1797	Dorothy Russell Memorial Lecture. The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?. 1994 , 20, 322-38		21
1796	Synthetic post-translationally modified human A beta peptide exhibits a markedly increased tendency to form beta-pleated sheets in vitro. 1994 , 221, 959-64		43
1795	Hydrolysis of amyloid precursor protein-derived peptides by cysteine proteinases and extracts of rat brain clathrin-coated vesicles. 1994 , 15, 175-82		23
1794	Toward an integrated discovery and development program in Alzheimer's disease: the amyloid hypothesis. 1994 , 15 Suppl 2, S105-9		5
1793	Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. 1994 , 67, 1216-28		325
1792	Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). 1994 , 13, 45-53		1509
1791	Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. 1994 , 47, 1275-84		96
1790	Research on Alzheimer's disease in Japan: a personal view on history and present status. 1994 , 19, 89-104		2
1789	A chemical approach to elucidate tin mechanism of transthyretin and E protein amyloid fibril formation. 1994 , 1, 186-205		97
1788	Endosome-lysosomes and neurodegeneration. 1994 , 48, 282-6		7

1787	Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. 1994 , 10, 373-403		649
1786	Amyloid beta-protein precursor: new clues to the genesis of Alzheimer's disease. 1994 , 4, 708-16		89
1785	Reversible random coil-beta-sheet transition of the Alzheimer beta-amyloid fragment (25-35). <i>Biochemistry</i> , 1994 , 33, 1345-50	3.2	139
1784	Peptide Mapping of Peanut Proteins: Identification of Peptides as Potential Indicators of Peanut Maturity. 1994 , 42, 623-628		9
1783	Racemization: its biological significance on neuropathogenesis of Alzheimer's disease. 1994 , 174, 251-62		41
1782	The amyloid beta protein precursor mutations linked to familial Alzheimer's disease alter processing in a way that fosters amyloid deposition. 1994 , 174, 217-23		21
1781	Advanced glycation end products contribute to amyloidosis in Alzheimer disease. 1994 , 91, 4766-70		682
1780	Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. 1994 , 91, 8378-82		372
1779	Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. 1995 , 92, 763-7		322
1778	The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. 1995 , 270, 3063-7		265
1777	The toxicity in vitro of beta-amyloid protein. 1995 , 311 (Pt 1), 1-16		430
1776	Molecular biology and genetics of Alzheimer's disease. 1995 , 2, 465-76		2
1775	Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. 1995 , 37, 294-9		351
1774	Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. 1995 , 90, 472-7		48
1773	A biotechnological method provides access to aggregation competent monomeric Alzheimer's 1-42 residue amyloid peptide. 1995 , 13, 988-93		42
1772	Untangling the pathophysiochemistry of beta-amyloid. 1995 , 2, 926-8		32
1771	Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. 1995 , 2, 990-8		398
1770	The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease?. 1995 , 2, 163-9		236

1769	Free radical theory of aging: Alzheimer's disease pathogenesis. 1995 , 18, 97-119		77
1768	Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. 1995 , 679, 151-6		63
1767	Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. 1995 , 702, 275-8		24
1766	The immunoreactive profile at the N-terminal region of A beta 1-39/40 but not A beta 1-42 changes with transition from monomer/dimer to further peptide aggregates. 1995 , 703, 237-241		13
1765	The COOH-terminus of the Alzheimer amyloid A β peptide: Differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parenchymal and vessel-associated amyloid deposits. 1995 , 2, 195-203		13
1764	Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. 1995 , 92, 2959-63		173
1763	The impact of genetic and environmental factors on the pathobiology of Alzheimer's disease: a multifactorial disorder?. 1995 , 7, 361-383		2
1762	Immunohistochemical analysis of COOH-termini of amyloid beta protein (A β) using end-specific antisera for A β 0 and A β 2 in Alzheimer's disease and normal aging. 1995 , 2, 7-16		21
1761	Domain formation induced by lipid-ion and lipid-peptide interactions. 1995 , 12, 51-7		26
1760	Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. 1995 , 270, 26041-4		66
1759	Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. 1995 , 270, 9564-70		306
1758	Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. 1995 , 270, 23895-8		245
1757	Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). 1995 , 270, 7013-6		512
1756	The Amyloid Peptide and Its Precursor in Alzheimer's Disease. 1995 , 6,		23
1755	Zinc and Alzheimer's disease. 1995 , 268, 1920-1; author reply 1921-3		10
1754	Transgenic mice and modeling Alzheimer's disease. 1995 , 6, 87-96		6
1753	Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4. <i>Biochemistry</i> , 1995 , 34, 724-30	3.2	321
1752	Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. <i>Biochemistry</i> , 1995 , 34, 10139-45	3.2	212

1751	1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. <i>Biochemistry</i> , 1995 , 34, 5191-200	3.2	185
1750	Long amyloid beta-protein secreted from wild-type human neuroblastoma IMR-32 cells. <i>Biochemistry</i> , 1995 , 34, 10272-8	3.2	155
1749	Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain. 1995 , 193, 105-8		43
1748	Carboxyl end-specific monoclonal antibodies to amyloid beta protein (A beta) subtypes (A beta 40 and A beta 42(43)) differentiate A beta in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys. 1995 , 201, 151-4		36
1747	Amyloid beta protein in rat soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: immunohistochemical evidence for amyloid beta protein. 1995 , 202, 77-80		14
1746	Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. 1995 , 4, 23-32		154
1745	New hopes arise with the transgenic model for Alzheimer's disease. 1995 , 16, 701-3		1
1744	Two conformational states of amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. 1995 , 186, 115-8		64
1743	Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis). 1995 , 2, 269-279		45
1742	Elevated A β levels in Alzheimer's disease brain are associated with selective accumulation of A β 2 in parenchymal amyloid plaques and both A β 0 and A β 2 in cerebrovascular deposits. 1995 , 2, 234-240		15
1741	Solvent effects on self-assembly of beta-amyloid peptide. 1995 , 69, 640-51		258
1740	In situ characterization of beta-amyloid in Alzheimer's diseased tissue by synchrotron Fourier transform infrared microspectroscopy. 1996 , 71, 1672-9		198
1739	Accumulation of beta-amyloid fibrils in pancreas of transgenic mice. 1996 , 17, 215-22		65
1738	Carboxy terminal of beta-amyloid deposits in aged human, canine, and polar bear brains. 1996 , 17, 249-57		57
1737	APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. 1996 , 17, 153-71		44
1736	Diffuse plaques contain C-terminal A beta 42 and not A beta 40: evidence from cats and dogs. 1996 , 17, 653-9		31
1735	Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides. 1996 , 17, 773-80		98
1734	Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. 1996 , 141, 65-8		138

1733	Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. 1996, 777, 175-82		23
1732	Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide. 1996, 777, 344-55		1
1731	A Reductionist View of Alzheimer's Disease. 1996, 29, 317-321		94
1730	Nicotine inhibits amyloid formation by the beta-peptide. <i>Biochemistry</i> , 1996, 35, 13568-78	3.2	214
1729	Conformations of synthetic beta peptides in solid state and in aqueous solution: relation to toxicity in PC12 cells. 1996, 1315, 40-6		22
1728	'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. 1996, 1316, 35-42		36
1727	Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. 1996, 256, 870-7		332
1726	Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. 1996, 3, 16-32		459
1725	Association of A beta 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. 1996, 5, 13-7		47
1724	Nuclear and cytoplasmic localization of the beta-amyloid peptide (1-43) in transfected 293 cells. 1996, 220, 710-8		27
1723	Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. 1996, 226, 672-80		406
1722	Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. 1996, 2, 864-70		2305
1721	Arrest of beta-amyloid fibril formation by a pentapeptide ligand. 1996, 271, 8545-8		756
1720	Transgenic models of neurodegenerative diseases. 1996, 6, 651-60		26
1719	Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. 1996, 16, 881-91		924
1718	Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. 1996, 17, 1005-13		1350
1717	Selective inhibition of Abeta fibril formation. 1996, 271, 4086-92		158
1716	Inhibitors of the Maillard Reaction. 1996, 6, 167-177		8

1715	A strategy for designing inhibitors of beta-amyloid toxicity. 1996 , 271, 29525-8	180
1714	Systemic overexpression of a C-terminal fragment of human amyloid beta-protein precursor causes accumulation of Alzheimer beta-amyloid fibrils in pancreas of transgenic mice. 1996 , 42 Suppl 1, 48-56	8
1713	Two-hybrid system as a model to study the interaction of beta-amyloid peptide monomers. 1996 , 93, 2065-70	52
1712	The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis. 1996 , 314 (Pt 2), 701-7	110
1711	Properties of some peptides related to amyloid beta-peptide. 1996 , 24, 59S	
1710	Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. 1996 , 93, 13170-5	269
1709	Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. 1996 , 16, 7533-9	275
1708	Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A beta-containing lesions in brains of patients with dementia of the Alzheimer type. 1996 , 91, 608-15	30
1707	The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: a review. 1996 , 27, 225-47	62
1706	Radical changes in beta-amyloid form and function. 1996 , 28, 49-55	2
1705	A beta A4 amyloid precursor protein gene and Alzheimer's disease. 1996 , 237, 6-15	30
1704	Brain amyloid--a physicochemical perspective. 1996 , 6, 147-62	60
1703	Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). 1996 , 40, 149-56	196
1702	Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. 1996 , 46, 58-66	58
1701	Amyloid precursor protein truncated at any of the gamma-secretase sites is not cleaved to beta-amyloid. 1996 , 46, 283-93	30
1700	Canine leptomenigeal organ culture: a new experimental model for cerebrovascular beta-amyloidosis. 1996 , 68, 143-8	7
1699	Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. 1996 , 3, 351-8	66
1698	A specific structural interaction of Alzheimer's peptide A beta 1-42 with alpha 1-antichymotrypsin. 1996 , 3, 668-71	38

1697	Neuropathology in the Down's syndrome brain. 1996 , 2, 31-2	21
1696	The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. 1996 , 2, 1146-50	440
1695	A comprehensive investigation of plasma and brain regional pharmacokinetics of imipramine and its metabolites during and after chronic administration in the rat. 1996 , 85, 291-5	13
1694	Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog. 1996 , 85, 396-401	15
1693	The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. 1996 , 271, 28655-9	135
1692	Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein. 1996 , 271, 1343-8	52
1691	The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. 1996 , 271, 10602-6	98
1690	Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. 1996 , 271, 28757-65	130
1689	Amyloid beta-protein and the genetics of Alzheimer's disease. 1996 , 271, 18295-8	654
1688	The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. 1996 , 271, 33623-31	110
1687	The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-beta 1-42 in Alzheimer's disease. 1996 , 271, 32185-91	74
1686	The A4 amyloid precursor protein gene and Alzheimer's disease. 1996 , 89-98	
1685	The role of the Maillard reaction in other pathologies: Alzheimer's disease. 1996 , 11 Suppl 5, 7-12	33
1684	A beta amyloidogenesis: unique, or variation on a systemic theme?. 1997 , 32, 361-404	69
1683	Molecular neurobiology of Alzheimer's disease (syndrome?). 1997 , 5, 177-213	26
1682	Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. 1997 , 272, 26464-70	253
1681	Soluble amyloid Abeta-(1-40) exists as a stable dimer at low concentrations. 1997 , 272, 21037-44	178
1680	The self catalytic enzyme inactivation induced by solvent stirring: a new example of protein conformational change induction. 1997 , 10, 1235-40	14

1679	Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. 1997 , 272, 7977-82	236
1678	Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. 1997 , 6, 1951-9	140
1677	Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. 1997 , 272, 22364-72	859
1676	The role of amyloid in the pathogenesis of Alzheimer's disease. 1997 , 378, 937-50	33
1675	Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice. 1997 , 6, 1535-41	90
1674	Exploring the Etiology of Alzheimer Disease Using Molecular Genetics. 1997 , 277, 825	132
1673	The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). 1997 , 48, 741-5	105
1672	The presenilins and Alzheimer's disease. 1997 , 6, 1639-46	145
1671	The Alzheimer family of diseases: many etiologies, one pathogenesis?. 1997 , 94, 2095-7	200
1670	Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer disease. 1997 , 94, 8208-13	235
1669	Fibril Formation by an Amphipathic .ALPHA.-Helix-Forming Polypeptide Produced by Gene Engineering.. 1997 , 73, 7-11	49
1668	The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue. 1997 , 94, 2025-30	351
1667	Apoptosis in neurodegenerative diseases. 1997 , 41, 337-68	15
1666	Chapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis. 1997 , 11-20	4
1665	Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid peptides. 1997 , 7, 1115-1127	9
1664	Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. <i>Biochemistry</i> , 1997 , 36, 8393-400	3,2 178
1663	Determination of Peptide Amide Configuration in a Model Amyloid Fibril by Solid-State NMR. 1997 , 119, 10487-10493	52
1662	Site-Specific Poly(ethylene glycol)ylation of Peptides. 1997 , 218-238	8

1661	Mutations in the transmembrane domain of APP altering gamma-secretase specificity. <i>Biochemistry</i> , 1997 , 36, 15396-403	3.2	97
1660	The systemic amyloidoses. 1997 , 337, 898-909		968
1659	Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. 1997 , 148, 41-5		134
1658	Reactive oxygen species and Alzheimer's disease. 1997 , 54, 533-9		199
1657	Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. <i>Biochemistry</i> , 1997 , 36, 6243-50	3.2	103
1656	Specific increase in amyloid beta-protein 42 secretion ratio by calpain inhibition. <i>Biochemistry</i> , 1997 , 36, 8377-83	3.2	62
1655	beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. 1997 , 10, 495-506		305
1654	Alzheimer's disease: genotypes, phenotypes, and treatments. 1997 , 275, 630-1		826
1653	A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. 1997 , 232, 652-5		98
1652	Amyloid beta-protein(25-35) increases cellular APP and inhibits the secretion of APPs in human extraneuronal cells. 1997 , 234, 336-40		22
1651	Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. 1997 , 272, 348-61		244
1650	The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. 1997 , 119, 59-71		207
1649	Biology of A beta amyloid in Alzheimer's disease. 1997 , 4, 313-28		187
1648	Amyloid precursor protein, copper and Alzheimer's disease. 1997 , 51, 105-11		39
1647	Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. 1997 , 19, 939-45		885
1646	Self-seeded fibers formed by Sup35, the protein determinant of [PSI ⁺], a heritable prion-like factor of <i>S. cerevisiae</i> . 1997 , 89, 811-9		548
1645	Small heat shock proteins inhibit in vitro A beta(1-42) amyloidogenesis. 1997 , 416, 117-21		88
1644	Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. 1997 , 66, 385-407		1439

1643	Amyloid, the presenilins and Alzheimer's disease. 1997 , 20, 154-9	1239
1642	Amyloid beta protein and transthyretin, sequestering protein colocalize in normal human kidney. 1997 , 222, 163-6	20
1641	Intracellular and secreted Alzheimer beta-amyloid species are generated by distinct mechanisms in cultured hippocampal neurons. 1997 , 94, 4125-30	144
1640	Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid β Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer's Disease and Cerebral Amyloid Angiopathy Cases. 1997 , 3, 695-707	137
1639	Nontoxic amyloid beta peptide 1-42 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer's disease. 1997 , 272, 2038-41	126
1638	Amyloid beta-protein (A β) 1-40 but not A β 1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. 1997 , 17, 8187-93	91
1637	[Changes found in the brain of people over 65 years old and their correlation with Alzheimer disease]. 1997 , 55, 298-304	
1636	Magnetic resonance spectroscopic changes in Alzheimer's disease. 1997 , 826, 282-306	48
1635	Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. 1997 , 3, 67-72	1183
1634	Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and beta-amyloid precursor protein. 1997 , 3, 328-32	217
1633	Distinct sites of intracellular production for Alzheimer's disease A beta40/42 amyloid peptides. 1997 , 3, 1016-20	649
1632	Rapid drug screening for Alzheimer's. 1997 , 15, 223-4	
1631	Yeast prions: inheritance by seeded protein polymerization?. 1997 , 7, R617-9	4
1630	Observation of metastable A β amyloid protofibrils by atomic force microscopy. 1997 , 4, 119-25	585
1629	Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. 1997 , 245, 355-63	160
1628	Cathepsin D displays in vitro beta-secretase-like specificity. 1997 , 750, 11-9	88
1627	Co-localization of beta-amyloid peptides, apolipoprotein E and glial markers in senile plaques in the prefrontal cortex of old rhesus monkeys. 1997 , 751, 315-22	28
1626	Characterization of amyloid beta protein species in cerebral amyloid angiopathy of a squirrel monkey by immunocytochemistry and enzyme-linked immunosorbent assay. 1997 , 764, 225-9	14

1625	Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease. 1997 , 768, 208-14	24
1624	Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. 1997 , 22, 49-56	148
1623	Media from rhabdomyosarcoma and neuroblastoma cell cultures stimulate in vitro aggregation and fibrillization of amyloid beta-protein. 1997 , 22, 227-32	6
1622	Metallothioneins in brain--the role in physiology and pathology. 1997 , 142, 229-42	164
1621	Variable deposition of amyloid beta-protein (A beta) with the carboxy-terminus that ends at residue valine40 (A beta 40) in the cerebral cortex of patients with Alzheimer's disease: a double-labeling immunohistochemical study with antibodies specific for A beta 40 and the A beta that ends at residues alanine42/threonine43 (A beta 42). 1997 , 22, 1499-506	23
1620	Deposition of amyloid beta protein (A beta) subtypes [A beta 40 and A beta 42(43)] in canine senile plaques and cerebral amyloid angiopathy. 1997 , 94, 323-8	26
1619	Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. 1997 , 4, 951-9	362
1618	Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. 1997 , 1, 260-7	57
1617	Spectroscopic studies on the conformational transitions of a bovine growth hormone releasing factor analog. 1997 , 53A, 1889-900	2
1616	Caffeine stimulates amyloid beta-peptide release from beta-amyloid precursor protein-transfected HEK293 cells. 1997 , 69, 1580-91	65
1615	Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer's disease: the Volga German families. 1997 , 41, 52-7	53
1614	Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. 1997 , 41, 271-3	99
1613	Amyloid beta-protein deposition in the leptomeninges and cerebral cortex. 1997 , 42, 899-908	39
1612	Butyrylcholinesterase in the life cycle of amyloid plaques. 1997 , 42, 909-18	241
1611	Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. 1997 , 18, 527-32	125
1610	Polymerization mechanism of polypeptide chain aggregation. 1997 , 54, 333-43	73
1609	Expression of mutant amyloid precursor proteins induces apoptosis in PC12 cells. 1997 , 47, 253-263	60
1608	The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid. 1998 , 31, 409-15	38

1607	Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides. 1998 , 23, 135-40	34
1606	Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. 1998 , 4, 1318-20	1259
1605	Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. 1998 , 1, 355-8	274
1604	Evidence for presenilin-1 involvement in amyloid angiopathy in the Alzheimer's disease-affected brain. 1998 , 789, 307-14	4
1603	The role of A beta 42 in Alzheimer's disease. 1998 , 92, 289-92	213
1602	The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide. 1998 , 256, 560-9	28
1601	The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. 1998 , 8, 447-53	766
1600	Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. 1998 , 43, 256-8	107
1599	Design of peptides undergoing self-catalytic alpha-to-beta transition and amyloidogenesis. 1998 , 47, 83-92	34
1598	Molecular simulation of the primary and secondary structures of the Abeta(1-42)-peptide of Alzheimer's disease. 1998 , 18, 403-30	27
1597	C-terminal truncation of the Sup35 protein increases the frequency of de novo generation of a prion-based [PSI ⁺] determinant in <i>Saccharomyces cerevisiae</i> . 1998 , 34, 146-51	54
1596	Monogenetic determinants of Alzheimer's disease: APP mutations. 1998 , 54, 897-901	28
1595	The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. 1998 , 56, 541-69	179
1594	Amyloid beta neurotoxicity in the cholinergic but not in the serotonergic phenotype of RN46A cells. 1998 , 57, 266-74	33
1593	Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. 1998 , 19, 161-3	33
1592	Metabolism of presenilin 1: influence of presenilin 1 on amyloid precursor protein processing. 1998 , 19, S15-8	7
1591	Abeta42, presenilins, and Alzheimer's disease. 1998 , 19, S11-3	13
1590	The effects of beta/A4-amyloid and its fragments on calcium homeostasis, glial fibrillary acidic protein and S100beta staining, morphology and survival of cultured hippocampal astrocytes. 1998 , 85, 1151-60	30

1589	Mutant human presenilin 1 protects presenilin 1 null mouse against embryonic lethality and elevates Aβ _{1-42/43} expression. 1998 , 20, 611-7		169
1588	Laminin blocks the assembly of wild-type A beta and the Dutch variant peptide into Alzheimer's fibrils. 1998 , 5, 16-23		30
1587	The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. <i>Biochemistry</i> , 1998 , 37, 15247-53	3.2	152
1586	Structural and kinetic features of amyloid beta-protein fibrillogenesis. 1998 , 5, 121-42		248
1585	Solution Structure Model of Residues 108 of the Amyloid β Peptide When Bound to Micelles. 1998 , 120, 11082-11091		74
1584	Solution structure of methionine-oxidized amyloid beta-peptide (1-40). Does oxidation affect conformational switching?. <i>Biochemistry</i> , 1998 , 37, 12700-6	3.2	140
1583	Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is?. <i>Biochemistry</i> , 1998 , 37, 11064-77	3.2	460
1582	Phosphatidylinositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. 1998 , 278, 183-94		121
1581	Presenilins upregulate functional K ⁺ channel currents in mammalian cells. 1998 , 4, 398-409		23
1580	Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. <i>Biochemistry</i> , 1998 , 37, 3602-11	3.2	183
1579	A nucleated assembly mechanism of Alzheimer paired helical filaments. 1998 , 95, 15712-7		292
1578	Bioorganic Chemistry: A Natural and Unnatural Science. 1998 , 75, 705		13
1577	The alpha5beta1 integrin mediates elimination of amyloid-beta peptide and protects against apoptosis. 1998 , 141, 1019-30		81
1576	Molecular modeling of the Aβ ₁₋₄₂ peptide from Alzheimer's disease. 1998 , 11, 761-7		77
1575	Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides. Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of Aβ ₄₂ . 1998 , 273, 21153-60		68
1574	The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer's disease. 1998 , 7, 519-26		1
1573	Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. 1998 , 273, 32730-8		615
1572	γ-secretase cleavage is distinct from endoplasmic reticulum degradation of the transmembrane domain of the amyloid precursor protein. 1998 , 273, 31947-55		27

1571	Inhibition of Alzheimer beta-fibrillogenesis by melatonin. 1998 , 273, 7185-8	260
1570	The proteolytic fragments of the Alzheimer's disease-associated presenilin-1 form heterodimers and occur as a 100-150-kDa molecular mass complex. 1998 , 273, 3205-11	284
1569	Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. 1998 , 141, 1031-9	261
1568	Temperature dependence of amyloid beta-protein fibrillization. 1998 , 95, 12277-82	229
1567	Molecular Simulation of the Amyloid β Peptide A β (1-40) of Alzheimer's Disease. 1998 , 20, 201-222	13
1566	Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease. 1998 , 55, 1001-4	56
1565	BetaAPP gamma-secretase and SREBP site 2 protease are two different enzymes. 1998 , 9, 911-3	8
1564	Genetic risk factors in Alzheimer's disease. 1998 , 51, 293-304	35
1563	Alzheimer disease. 1998 , 42, 1-54	166
1562	Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. 1998 , 95, 6448-53	2970
1561	beta-Amyloid toxicity in rat brain reaggregate cultures. 1998 , 26, S240	1
1560	Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. 1998 , 18, 2161-73	308
1559	Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. 1998 , 18, 1743-52	210
1558	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. 1998 , 3, d436-46	18
1557	Alzheimer's disease and heparan sulfate proteoglycan. 1998 , 3, d327-37	24
1556	Electrophoretic separation and immunoblotting of a β (1-40) and a β (1-42). 2000 , 32, 91-9	5
1555	Quantifying A β (1-40) and A β (1-42) Using Sandwich-ELISA. 2000 , 32, 79-89	3
1554	Using β Secretase Inhibitors to Distinguish the Generation of the A β Peptides Terminating at Val-40 and Ala-42. 2000 , 32, 239-48	2

1553	The neurobiology and pharmacotherapy of Alzheimer's disease. 1999 , 11, 19-31	43
1552	Molecular modeling of the amyloid-beta-peptide using the homology to a fragment of triosephosphate isomerase that forms amyloid in vitro. 1999 , 12, 959-66	11
1551	A molecular model of Alzheimer amyloid beta-peptide fibril formation. 1999 , 274, 12619-25	306
1550	Design and testing of inhibitors of fibril formation. 1999 , 309, 476-88	16
1549	Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. 1999 , 274, 20650-6	93
1548	A notable cleavage: winding up with beta-amyloid. 1999 , 96, 2574-6	8
1547	Analysis of amyloid-beta assemblies using tapping mode atomic force microscopy under ambient conditions. 1999 , 309, 510-25	23
1546	Distribution and fluidizing action of soluble and aggregated amyloid beta-peptide in rat synaptic plasma membranes. 1999 , 274, 18801-7	104
1545	Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. 1999 , 96, 3053-8	206
1544	Manipulating the amyloid-beta aggregation pathway with chemical chaperones. 1999 , 274, 32970-4	201
1543	The presenilins as potential drug targets in Alzheimer's disease. 1999 , 3, 413-422	1
1542	Hereditary cerebral hemorrhage with amyloidosis--Dutch type (HCHWA-D): a review of the variety in phenotypic expression. 1999 , 6, 215-24	26
1541	Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. 1999 , 274, 32301-8	157
1540	Rank-order of potencies for inhibition of the secretion of abeta40 and abeta42 suggests that both are generated by a single gamma-secretase. 1999 , 274, 20499-504	40
1539	The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. 1999 , 122 (Pt 9), 1709-19	99
1538	Endogenous proteins controlling amyloid beta-peptide polymerization. Possible implications for beta-amyloid formation in the central nervous system and in peripheral tissues. 1999 , 274, 15990-5	123
1537	Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. 1999 , 96, 3342-4	516
1536	In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. 1999 , 96, 3688-93	377

1535	Amyloid beta-peptide polymerization studied using fluorescence correlation spectroscopy. 1999 , 6, 53-62	134
1534	The amyloid precursor protein of Alzheimer's disease and the Abeta peptide. 1999 , 25, 81-97	129
1533	Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. 1999 , 266, 1101-10	205
1532	Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. 1999 , 893, 314-20	82
1531	Translating cell biology into therapeutic advances in Alzheimer's disease. 1999 , 399, A23-31	1214
1530	In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation. 1999 , 6, 7-13	82
1529	Platelet membrane fluidity individuals at risk for Alzheimer's disease: a comparison of results from fluorescence spectroscopy and electron spin resonance spectroscopy. 1999 , 145, 175-80	79
1528	Ultrastructural evidence of early non-fibrillar Abeta42 in the capillary basement membrane of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type. 1999 , 98, 577-82	44
1527	Intracellular biology of Alzheimer's disease amyloid beta peptide. 1999 , 249, 291-8	60
1526	A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. 1999 , 93, 182-93	262
1525	Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42). 1999 , 815, 1-10	67
1524	Implications of presenilin 1 mutations in Alzheimer's disease. 1999 , 107, 281-98	3
1523	Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. 1999 , 5, 343-50	107
1522	Separation of tubulin isoforms by isoelectric focusing in immobilized pH gradient gels. 1999 , 275, 265-7	38
1521	Semiquantitative analysis of amyloid beta peptides using a combination of immunoprecipitation and matrix-assisted laser desorption ionization/ time-of-flight-mass spectrometry. 1999 , 275, 262-5	9
1520	Occurrence of the diffuse amyloid beta-protein (Abeta) deposits with numerous Abeta-containing glial cells in the cerebral cortex of patients with Alzheimer's disease. 1999 , 25, 324-31	82
1519	Death of PC12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression. 1999 , 55, 629-42	36
1518	Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. 1999 , 309, 375-86	193

1517	Alzheimer's Disease. 1999 ,		
1516	alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. 1999 , 274, 19509-12		523
1515	⊖Amyloid Disrupting Drugs. 1999 , 12, 347-356		10
1514	Complement activation by the amyloid proteins A beta peptide and beta 2-microglobulin. 1999 , 6, 265-72		11
1513	Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain. 1999 , 42, 2805-15		80
1512	New clothes for amyloid enhancing factor (AEF): silk as AEF. 1999 , 6, 98-106		51
1511	In vitro processing of amyloid precursor protein by cathepsin D. 1999 , 31, 1327-37		36
1510	Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. 1999 , 90, 1-13		270
1509	Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner. 1999 , 90, 1217-26		99
1508	Hypothesis: amyloid beta-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. 1999 , 20, 65-9		30
1507	Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. 1999 , 20, 249-57		29
1506	Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. <i>Biochemistry</i> , 1999 , 38, 15514-21	3.2	187
1505	Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. 1999 , 274, 25945-52		871
1504	Effects of sequential proline substitutions on amyloid formation by human amylin ₂₀₋₂₉ . <i>Biochemistry</i> , 1999 , 38, 1811-8	3.2	178
1503	An atomic model for the pleated beta-sheet structure of Abeta amyloid protofilaments. 1999 , 76, 2871-8		110
1502	Peptidomimetic probes and molecular modeling suggest that Alzheimer's gamma-secretase is an intramembrane-cleaving aspartyl protease. <i>Biochemistry</i> , 1999 , 38, 4720-7	3.2	300
1501	Deposition of monomeric, not oligomeric, Abeta mediates growth of Alzheimer's disease amyloid plaques in human brain preparations. <i>Biochemistry</i> , 1999 , 38, 10424-31	3.2	119
1500	Residue-Specific pKa Measurements of the ⊖Peptide and Mechanism of pH-Induced Amyloid Formation. 1999 , 121, 8698-8706		85

1499	Modified-peptide inhibitors of amyloid beta-peptide polymerization. <i>Biochemistry</i> , 1999 , 38, 6791-800	3.2	216
1498	Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. <i>Biochemistry</i> , 1999 , 38, 11223-30	3.2	191
1497	Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. 1999 , 155, 23-8		57
1496	A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. 1999 , 155, 123-33		67
1495	Mouse senile amyloid deposition is suppressed by adenovirus-mediated overexpression of amyloid-resistant apolipoprotein A-II. 1999 , 155, 1319-26		16
1494	Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (A β) dimer in the cortex during aging. 1999 , 154, 271-9		89
1493	Assembly of A β amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. <i>Biochemistry</i> , 1999 , 38, 8972-80	3.2	458
1492	Morphological development of beta(1-40) amyloid fibrils. 1999 , 158, 437-43		33
1491	Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. 1999 , 294, 1375-85		125
1490	Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. 1999 , 6, 190-9		74
1489	Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. 1999 , 6, 231-44		156
1488	Effects of the amyloid precursor protein Glu693->Gln Dutch mutation on the production and stability of amyloid β protein. 1999 , 340, 703-709		54
1487	Proteolytic processing and degradation of Alzheimer's disease relevant proteins. 1999 , 27, 234-42		5
1486	Effects of the amyloid precursor protein Glu693->Gln Dutch mutation on the production and stability of amyloid β protein. 1999 , 340, 703		18
1485	Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A β 40 and A β 42. 1999 , 10, 2965-9		49
1484	Amyloid .BETA. Peptides and Presenilins in the Pathogenesis of Alzheimer's Disease.. 1999 , 32, 13-15		5
1483	Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β amyloid peptide. 2000 , 348, 137		47
1482	Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β amyloid peptide. 2000 , 348, 137-144		124

1481	Chapter 4. Secretase inhibitors as therapeutics for Alzheimer's disease. 2000 , 35, 31-40	11
1480	Amyloid beta protein (Abeta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. 2000 , 59, 723-32	74
1479	Amyloid beta-protein length and cerebral amyloid angiopathy-related haemorrhage. 2000 , 11, 937-40	26
1478	Age-related amyloid beta protein accumulation induces cellular death and macrophage activation in transgenic mice. 2000 , 191, 93-101	7
1477	Gel electrophoretic distinction between Congo Red nonreactive beta-amyloid (1-42) and beta-amyloid (1-40). 2000 , 21, 760-1	3
1476	Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis. 2000 , 74, 1131-9	28
1475	Constitutive overactivation of protein kinase C in guinea pig brain increases alpha-secretory APP processing without decreasing beta-amyloid generation. 2000 , 12, 3191-200	36
1474	Examining the zinc binding site of the amyloid-beta peptide. 2000 , 267, 6692-8	99
1473	Solid-state NMR as a probe of amyloid fibril structure. 2000 , 4, 500-6	78
1472	Inhibiting the conversion of soluble amyloid-beta peptide into abnormally folded amyloidogenic intermediates: relevance for Alzheimer's disease therapy. 2000 , 176, 90-5	26
1471	Amyloid fibrillogenesis: themes and variations. 2000 , 10, 60-8	977
1470	Temperature-dependent beta-sheet formation in beta-amyloid Abeta(1-40) peptide in water: uncoupling beta-structure folding from aggregation. 2000 , 1476, 93-102	113
1469	Aggregation of an amyloidogenic fragment of human islet amyloid polypeptide. 2000 , 1476, 230-8	47
1468	Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. 2000 , 25, 247-55	188
1467	Conformational transitions and fibrillation mechanism of human calcitonin as studied by high-resolution solid-state ¹³ C NMR. 2000 , 9, 867-77	97
1466	Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. 2000 , 22, 81-98	36
1465	Alzheimer's disease, beta-amyloid protein and zinc. 2000 , 130, 1488S-92S	84
1464	Amyloid-beta and treatment opportunities for Alzheimer's disease. 2000 , 2, 231-59	5

1463	A conformation change in the carboxyl terminus of Alzheimer's Abeta (1-40) accompanies the transition from dimer to fibril as revealed by fluorescence quenching analysis. 2000 , 275, 22645-9	39
1462	Alternate aggregation pathways of the Alzheimer beta-amyloid peptide. An in vitro model of preamyloid. 2000 , 275, 36436-40	64
1461	Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. 2000 , 97, 6138-43	504
1460	Regulation of amyloid precursor protein processing by presenilin 1 (PS1) and PS2 in PS1 knockout cells. 2000 , 275, 215-22	34
1459	Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin. 2000 , 275, 27901-8	70
1458	Transformation of beta-amyloid (A beta) (1-42) tyrosine to L-dopa as the result of in vitro hydroxyl radical attack. 2000 , 7, 189-93	10
1457	Amyloid-like protein structure in mammalian ocular lenses. 2000 , 20, 462-468	32
1456	Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. 2000 , 275, 16941-7	50
1455	Multiple quantum solid-state NMR indicates a parallel, not antiparallel, organization of beta-sheets in Alzheimer's beta-amyloid fibrils. 2000 , 97, 13045-50	352
1454	Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. 2000 , 97, 571-6	1312
1453	Association between complement regulatory protein factor H and AM34 antigen, detected in senile plaques. 2000 , 55, M265-9	8
1452	Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. 2000 , 275, 10437-42	142
1451	The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. 2000 , 275, 3173-8	201
1450	Inhibitors of beta-amyloid formation based on the beta-secretase cleavage site. 2000 , 268, 133-5	38
1449	Oligomerization and toxicity of beta-amyloid-42 implicated in Alzheimer's disease. 2000 , 273, 1003-7	159
1448	Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. 2000 , 276, 422-7	162
1447	Identification of a penta- and hexapeptide of islet amyloid polypeptide (IAPP) with amyloidogenic and cytotoxic properties. 2000 , 295, 1055-71	357
1446	Probing the kinetics of beta-amyloid self-association. 2000 , 130, 109-22	84

1445	A beta fibrillogenesis: kinetic parameters for fibril formation from congo red binding. 2000 , 130, 123-9		42
1444	Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. 2000 , 130, 184-208		611
1443	Review: modulating factors in amyloid-beta fibril formation. 2000 , 130, 259-70		200
1442	Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer's disease. 2000 , 355, 42-3		75
1441	Molecular insights into neurodevelopmental and neurodegenerative diseases. 2000 , 53, 455-69		21
1440	Does human betaA4 exert a protective function against oxidative stress in Alzheimer's disease?. 2000 , 54, 672-7		25
1439	In-situ atomic force microscopy study of beta-amyloid fibrillization. 2000 , 298, 833-40		172
1438	Approaches to discovery and characterization of inhibitors of amyloid beta-peptide polymerization. 2000 , 1502, 76-84		138
1437	Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. 2000 , 1502, 172-87		221
1436	Molecular assembly of endogenous and synthetic big atrial natriuretic peptide (ANP) and its amyloidogenic implications. 2000 , 1500, 31-40		8
1435	Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. 2000 , 9, 2589-98		112
1434	Alpha-B-crystallin in neuropathology. 2000 , 214, 7-12		45
1433	Tilted peptides: a motif for membrane destabilization (hypothesis). 2000 , 17, 31-40		68
1432	Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. <i>Biochemistry</i> , 2000 , 39, 10011-6	3.2	117
1431	Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design. 2000 , 43, 3434-42		64
1430	A distinct ER/IC gamma-secretase competes with the proteasome for cleavage of APP. <i>Biochemistry</i> , 2000 , 39, 810-7	3.2	71
1429	Fibril formation and neurotoxicity by a herpes simplex virus glycoprotein B fragment with homology to the Alzheimer's A beta peptide. <i>Biochemistry</i> , 2000 , 39, 5988-94	3.2	89
1428	Proteases as Targets for Therapy. 2000 ,		6

1427	Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. <i>Biochemistry</i> , 2001 , 40, 8073-84	3.2	247
1426	Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. <i>Biochemistry</i> , 2001 , 40, 8237-45	3.2	238
1425	Characterization of high-affinity binding between gangliosides and amyloid beta-protein. 2001 , 388, 225-30		125
1424	Role of cysteine-291 and cysteine-322 in the polymerization of human tau into Alzheimer-like filaments. 2001 , 285, 20-6		48
1423	Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. 2001 , 159, 439-47		240
1422	A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. 2001 , 81, 1805-22		233
1421	beta-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease. 2001 , 49, 72-85		39
1420	APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. 2001 , 31, 713-26		210
1419	Spontaneous in vitro formation of supramolecular beta-amyloid structures, "betaamy balls", by beta-amyloid 1-40 peptide. <i>Biochemistry</i> , 2001 , 40, 14736-43	3.2	60
1418	Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. <i>Biochemistry</i> , 2001 , 40, 3553-60	3.2	100
1417	Aspartyl protease inhibitor pepstatin binds to the presenilins of Alzheimer's disease. <i>Biochemistry</i> , 2001 , 40, 8359-68	3.2	43
1416	Secretase targets for Alzheimer's disease: identification and therapeutic potential. 2001 , 44, 2039-60		122
1415	Etiology, Genetics, and Pathogenesis of Alzheimer's Disease. 2001 , 333-348		
1414	Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. 2001 , 21, 372-81		870
1413	Alzheimer's disease: genes, proteins, and therapy. 2001 , 81, 741-66		4885
1412	The Association of Aluminium and [Amyloid in Alzheimer's Disease. 2001 , 421-433		4
1411	Therapeutic targets in the biology of Alzheimer's disease. 2001 , 14, 341-348		11
1410	Fibrillar amyloid beta-protein forms a membrane-like hydrophobic domain. 2001 , 12, 587-90		11

- 1409 Molecular Simulation of Solution Conformations of the Amyloid β Peptide A β (1-42) by a Backpropagation Neural Network Model. **2001**, 27, 43-59
- 1408 Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology. **2001**, 3, 241-248 23
- 1407 Parallels between the Redox Properties and Toxicity of A β in Alzheimer's Disease and Mutant Cu/Zn-SOD in Familial Amyotrophic Lateral Sclerosis. 393-406
- 1406 Synthesis of amyloid β peptides in solution employing chloroform-phenol mixed solvent for facile segment condensation of sparingly soluble protected peptides. **2001**, 8, 319-330 2
- 1405 High throughput screens for the identification of compounds that alter the accumulation of the Alzheimer's amyloid beta peptide (Abeta). **2001**, 108, 171-9 41
- 1404 Neurotoxic traffic: uncovering the mechanics of amyloid production in Alzheimer's disease. **2001**, 2, 75-81 19
- 1403 NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox). **2001**, 268, 5930-6 190
- 1402 The amyloid-beta peptide and its role in Alzheimer's disease. **2001**, 7, 227-49 83
- 1401 Interaction between synthetic amyloid-beta-peptide (1-40) and its aggregation inhibitors studied by electrospray ionization mass spectrometry. **2001**, 36, 1226-9 50
- 1400 Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. **2001**, 60, 438-59 94
- 1399 Energy landscape theory for Alzheimer's amyloid beta-peptide fibril elongation. **2001**, 42, 217-29 99
- 1398 Aggregated proteins accelerate but do not increase the aggregation of D-glyceraldehyde-3-phosphate dehydrogenase. Specificity of protein aggregation. **2001**, 20, 155-63 4
- 1397 Promotion of formation of amyloid fibrils by aluminium adenosine triphosphate (AlATP). **2001**, 84, 215-24 55
- 1396 Computational studies on the binding of β sheet breaker (BSB) peptides on amyloid A β (1-42). **2001**, 542, 25-31 7
- 1395 Is aggregation of beta-amyloid peptides a mis-functioning of a current interaction process?. **2001**, 1546, 356-64 4
- 1394 A portrait of Alzheimer secretases--new features and familiar faces. **2001**, 293, 1449-54 439
- 1393 Secretases as therapeutic targets for the treatment of Alzheimer's disease. **2001**, 8, 124-42 25
- 1392 Characterization of cholyl-leu-val-phe-phe-ala-OH as an inhibitor of amyloid beta-peptide polymerization. **2001**, 8, 231-41 30

1391	Statine-derived tetrapeptide inhibitors of β secretase. 2001 , 11, 1047-1050	2
1390	The Role of presenilins in gamma-secretase activity. 2001 , 276, 5413-6	108
1389	Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. 2001 , 276, 35235-8	237
1388	Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides. implications for drug development. 2001 , 276, 6412-9	62
1387	The Aetiology of Alzheimer's Disease: Diverse Routes into a Common Tau Pathway. 2001 , 97-132	1
1386	Intraneuronal A β 2 accumulation in Down syndrome brain. 2002 , 9, 88-102	209
1385	Structural and dynamic features of Alzheimer's A β peptide in amyloid fibrils studied by site-directed spin labeling. 2002 , 277, 40810-5	325
1384	Deciphering the genetic basis of Alzheimer's disease. 2002 , 3, 67-99	226
1383	Amyloid: morphology and toxicity. 2002 , 40, 1266-70	15
1382	Iron and Parkinson's disease. 2002 , 8, 22-32	66
1381	Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. Insights into transition states from pressure, temperature, and co-solute studies. 2002 , 277, 27240-6	49
1380	Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. 2002 , 9, 1751-62	42
1379	Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. 2002 , 277, 671-8	348
1378	Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation. 2002 , 99, 8666-71	222
1377	Assembling amyloid fibrils from designed structures containing a significant amyloid beta-peptide fragment. 2002 , 366, 343-51	47
1376	Beta-amyloid enhances glial glutamate uptake activity and attenuates synaptic efficacy. 2002 , 277, 32180-6	31
1375	The challenge of inhibiting A β polymerization. 2002 , 9, 1121-33	43
1374	Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. <i>Biochemistry</i> , 2002 , 41, 3128-36	3.2 98

1373	Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. <i>Biochemistry</i> , 2002 , 41, 1091-9	3.2	68
1372	A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. <i>Biochemistry</i> , 2002 , 41, 2825-35	3.2	318
1371	Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. <i>Biochemistry</i> , 2002 , 41, 15436-50	3.2	249
1370	Pentapeptide amides interfere with the aggregation of beta-amyloid peptide of Alzheimer's disease. 2002 , 292, 931-6		58
1369	Protein ectodomain shedding. 2002 , 102, 4627-38		209
1368	Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. <i>Biochemistry</i> , 2002 , 41, 6115-27	3.2	161
1367	Metal switch for amyloid formation: insight into the structure of the nucleus. 2002 , 124, 12644-5		69
1366	Disassembly of amyloid beta-protein fibril by basement membrane components. 2002 , 70, 2421-31		17
1365	Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis. 2002 , 319, 1279-90		198
1364	Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. 2002 , 23, 1205-14		64
1363	Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. 2002 , 23, 1285-97		132
1362	FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. 2002 , 23, 335-48		105
1361	Metal complexing agents as therapies for Alzheimer's disease. 2002 , 23, 1031-8		276
1360	A safer vaccine for Alzheimer's disease?. 2002 , 23, 1001-8		39
1359	Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro. 2002 , 322, 121-5		81
1358	Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. 2002 , 54, 469-525		354
1357	Alzheimer's disease: targets for drug development. 2002 , 2, 1-9		8
1356	Alzheimer's Amyloid Peptide and Free Radical Oxidative Stress. 2002 , 609-638		

1355	Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. 2002 , 954, 1-10	50
1354	A rare occurrence of a Eurn in an amyloid A4 peptide. 2002 , 40, 211-218	8
1353	Immunization for Alzheimer's disease. 2002 , 56, 135-142	8
1352	Cytosolic protein-protein interactions that regulate the amyloid precursor protein. 2002 , 56, 228-241	1
1351	Cholinergic abnormalities in Alzheimer's disease: are there new targets for drug development?. 2002 , 56, 369-379	2
1350	Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. 2002 , 19, 7-10	27
1349	Immunization treatment approaches in Alzheimer's and prion diseases. 2002 , 2, 400-4	5
1348	Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. 2002 , 2, 457-64	44
1347	Three-dimensional and fractal analyses of assemblies of amyloid beta protein subtypes [Abeta40 and Abeta42(43)] in canine senile plaques. 2002 , 103, 228-36	11
1346	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. 2002 , 27, 169-83	23
1345	Reversible inactivation of superoxide-sensitive aconitase in Abeta1-42-treated neuronal cell lines. 2000 , 75, 1977-85	34
1344	Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. 2002 , 81, 481-96	199
1343	Secretases as targets for drug design in Alzheimer's disease. 2002 , 32, 60-8	11
1342	Structural determinants of the Alzheimer's amyloid beta-peptide. 1994 , 63, 1191-8	128
1341	Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. 1995 , 65, 1431-44	353
1340	Amyloid precursor protein metabolism in primary cell cultures of neurons, astrocytes, and microglia. 1996 , 66, 2300-10	60
1339	High-resolution separation of amyloid beta-peptides: structural variants present in Alzheimer's disease amyloid. 1996 , 67, 294-301	22
1338	Rapid degeneration of cultured human brain pericytes by amyloid beta protein. 1997 , 68, 1135-41	125

1337	Aggregation of beta-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain. 1997 , 69, 266-72		19
1336	Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. 1997 , 69, 388-98		78
1335	Mutant presenilin 2 transgenic mouse: effect on an age-dependent increase of amyloid beta-protein 42 in the brain. 1998 , 71, 313-22		72
1334	Intracellular accumulation of detergent-soluble amyloidogenic A beta fragment of Alzheimer's disease precursor protein in the hippocampus of aged transgenic mice. 1999 , 72, 2479-87		60
1333	Coordination of copper(II) ions by the 11-20 and 11-28 fragments of human and mouse beta-amyloid peptide. 2002 , 92, 1-10		45
1332	Structural, kinetic and cytotoxicity aspects of 12-28 beta-amyloid protein fragment: a reappraisal. 2002 , 8, 578-88		21
1331	Presenilins are not required for A beta 42 production in the early secretory pathway. 2002 , 5, 849-55		89
1330	Therapeutic strategies for Alzheimer's disease. 2002 , 1, 859-66		144
1329	Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. 2002 , 973, 323-33		31
1328	Membrane destabilization induced by beta-amyloid peptide 29-42: importance of the amino-terminus. 2002 , 120, 57-74		35
1327	Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. <i>Biochemistry</i> , 2002 , 41, 13489-98	3.2	114
1326	Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. 2003 , 20, 15-24		32
1325	Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model. 2003 , 22, 31-40		44
1324	Guinea pigs as a nontransgenic model for APP processing in vitro and in vivo. 2003 , 28, 637-44		36
1323	Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. 2003 , 100, 330-5		1077
1322	Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. 2003 , 100, 10417-22		906
1321	Electrophoretic mobility of Alzheimer's amyloid-beta peptides in urea-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. 2003 , 323, 103-13		24
1320	Abeta species, including IsoAsp23 Abeta, in Iowa-type familial cerebral amyloid angiopathy. 2003 , 105, 252-8		30

1319	Emerging ideas on the molecular basis of protein and peptide aggregation. 2003 , 13, 146-59		289
1318	Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome. 2003 , 25, 180-5		36
1317	Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. 2003 , 74, 361-9		39
1316	Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. 2003 , 74, 393-405		35
1315	Peptide binding by one-armed receptors in water: screening of a combinatorial library for the binding of Val-Val-Ile-Ala. 2003 , 4, 1232-8		50
1314	Hypoxic remodelling of Ca ²⁺ mobilization in type I cortical astrocytes: involvement of ROS and pro-amyloidogenic APP processing. 2004 , 88, 869-77		22
1313	A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. 2003 , 125, 15359-65		143
1312	Hydrogen exchange-mass spectrometry analysis of beta-amyloid peptide structure. <i>Biochemistry</i> , 2003 , 42, 9507-14	3.2	55
1311	Insights into the amyloid folding problem from solid-state NMR. <i>Biochemistry</i> , 2003 , 42, 3151-9	3.2	191
1310	Degradation of beta-amyloid by proteolytic antibody light chains. <i>Biochemistry</i> , 2003 , 42, 14328-34	3.2	59
1309	Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. 2003 , 26, 267-98		1439
1308	Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. 2003 , 325, 743-57		87
1307	Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. 2003 , 180, 131-43		104
1306	Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. 2003 , 70, 1-32		545
1305	Specific uptake of Abeta1-40 in rat brain occurs in astrocyte, but not in microglia. 2003 , 342, 129-31		33
1304	Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic <i>Caenorhabditis elegans</i> model. 2003 , 24, 415-20		297
1303	Causative and susceptibility genes for Alzheimer's disease: a review. 2003 , 61, 1-24		241
1302	The amyloid beta peptide (Abeta(1-40)) is thermodynamically soluble at physiological concentrations. <i>Biochemistry</i> , 2003 , 42, 10506-13	3.2	154

1301	Probing the role of backbone hydrogen bonding in beta-amyloid fibrils with inhibitor peptides containing ester bonds at alternate positions. <i>Biochemistry</i> , 2003 , 42, 475-85	3.2	99
1300	Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. 2003 , 40, 25-40		82
1299	Cholesterol: from heart attacks to Alzheimer's disease. 2003 , 44, 1423-30		56
1298	Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. 2003 , 278, 35317-24		60
1297	Identification of a mutant amyloid peptide that predominantly forms neurotoxic protofibrillar aggregates. 2003 , 278, 23187-95		36
1296	Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. 2003 , 12, 3133-43		59
1295	Early synergy between Abeta42 and oxidatively damaged membranes in promoting amyloid fibril formation by Abeta40. 2003 , 278, 36277-84		48
1294	Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. 2003 , 278, 16528-33		109
1293	Secondary conformations and temperature effect on structural transformation of amyloid beta (1-28), (1-40) and (1-42) peptides. 2003 , 20, 595-601		15
1292	Atomic Force Microscopy. 2003 ,		8
1291	Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. 2003 , 26, 565-97		574
1290	Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. 2003 , 278, 4458-66		67
1289	Mouse models of Alzheimer's disease: the long and filamentous road. 2003 , 25, 590-600		46
1288	Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. 2003 , 2003, RE4		27
1287	Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. 2003 , 138, 400-10		93
1286	Chapter 5. Secretase inhibitors for Alzheimer's disease. 2003 , 38, 41-50		11
1285	The secretases of Alzheimer's disease. 2003 , 54, 233-61		28
1284	Using combinatorial methods to arrive at a quantitative structure-stability relationship for a new class of one-armed cationic peptide receptors targeting the C-terminus of the amyloid beta-peptide. 2003 , 1, 633-6		25

1283	Atomic force microscopy of beta-amyloid: static and dynamic studies of nanostructure and its formation. 2004 , 242, 349-64	3
1282	Transgenic mouse models of neurodegenerative disease. 2004 , 533-557	
1281	Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. 2004 , 1, 231-5	54
1280	Multiple plasma proteins control atrial natriuretic peptide (ANP) aggregation. 2004 , 33, 335-41	16
1279	The elongation of yeast prion fibers involves separable steps of association and conversion. 2004 , 101, 2287-92	81
1278	Alzheimer's disease: from bench to bedside. 2004 , 18, 177-195	
1277	Implications of transcriptional coactivator CREB binding protein complexes in rheumatoid arthritis. 2004 , 14, 6-11	4
1276	Functional implications of the presenilin dimerization: reconstitution of gamma-secretase activity by assembly of a catalytic site at the dimer interface of two catalytically inactive presenilins. 2004 , 279, 36519-29	50
1275	Active clearance of human amyloid beta 1-42 peptide aggregates from the rat ventricular system. 2004 , 24, 194-200	7
1274	CSF biomarkers for mild cognitive impairment. 2004 , 256, 224-34	122
1273	Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. 2004 , 10 Suppl, S26-33	138
1272	Strategies for disease modification in Alzheimer's disease. 2004 , 5, 677-85	361
1271	Proteases and lipoprotein receptors in Alzheimer's disease. 2004 , 41, 139-78	4
1270	Amyloid formation of a yeast prion determinant. 2004 , 23, 13-22	10
1269	Stabilization of discordant helices in amyloid fibril-forming proteins. 2004 , 13, 1251-9	50
1268	Redox-active metals, oxidative stress, and Alzheimer's disease pathology. 2004 , 1012, 153-63	329
1267	Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. 2004 , 9, 954-60	195
1266	Molecular modeling of the core of Abeta amyloid fibrils. 2004 , 57, 357-64	55

1265	Co-expressed presenilin 1 NTF and CTF form functional gamma-secretase complexes in cells devoid of full-length protein. 2004 , 89, 44-53		45
1264	Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. 2004 , 25, 2912-8		88
1263	Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. 2004 , 75, 162-71		140
1262	Alzheimer's beta-peptide oligomer formation at physiologic concentrations. 2004 , 335, 81-90		100
1261	Small assemblies of unmodified amyloid β protein are the proximate neurotoxin in Alzheimer's disease. 2004 , 25, 569-569		
1260	In silico assembly of Alzheimer's A β 16-22 peptide into beta-sheets. 2004 , 126, 11509-16		125
1259	Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. 2004 , 50, 419-31		16
1258	Modeling amyloid beta-peptide insertion into lipid bilayers. 2004 , 86, 3585-97		47
1257	The stability and dynamics of the human calcitonin amyloid peptide DFNKF. 2004 , 87, 146-58		44
1256	Cerebrospinal fluid protein biomarkers for Alzheimer's disease. 2004 , 1, 213-25		353
1255	Biomarkers of Alzheimer disease in plasma. 2004 , 1, 226-34		212
1254	Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. <i>Biochemistry</i> , 2004 , 43, 7365-81	3.2	281
1253	Novel aspects of accumulation dynamics and A β composition in transgenic models of AD. 2004 , 25, 1175-85		20
1252	Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. 2004 , 25, 569-80		437
1251	The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. 2004 , 44, 227-38		220
1250	Deciphering the molecular basis of memory failure in Alzheimer's disease. 2004 , 44, 181-93		1004
1249	Eight-residue A β peptides inhibit the aggregation and enzymatic activity of A β 42. 2004 , 120, 227-36		24
1248	Mostly separate distributions of CLAC- versus A β 40- or thioflavin S-reactivities in senile plaques reveal two distinct subpopulations of beta-amyloid deposits. 2004 , 165, 273-81		21

1247	Astroglial responses against Abeta initially occur in cerebral primary cortical cultures: species differences between rat and cynomolgus monkey. 2004 , 49, 339-46	10
1246	Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. 2004 , 25, 861-71	100
1245	A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. 2004 , 26, 365-75	216
1244	Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. 2004 , 335, 833-42	351
1243	Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. 2004 , 335, 997-1006	88
1242	Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers. 2004 , 339, 145-59	69
1241	Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. 2004 , 341, 575-88	114
1240	Alzheimer's disease Abeta peptide fragment 10-30 forms a spectrum of metastable oligomers with marked preference for N to N and C to C monomer termini proximity. 2004 , 344, 1037-49	19
1239	Amyloid and tau protein. 2004 , 4, S62-S69	
1238	Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. 2004 , 13, 159-70	1073
1237	Bioorganic Receptors for Amino Acids and Peptides: Combining Rational Design with Combinatorial Chemistry. 2004 , 140-154	0
1236	Role of Post-translational Chemical Modifications in Amyloid Fibril Formation. 81-109	3
1235	The Amyloid I-Protein. 384-491	2
1234	Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. 2005 , 97, 461-71	53
1233	Beta-amyloid protein structure determines the nature of cytokine release from rat microglia. 2005 , 27, 1-12	62
1232	Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. 2005 , 14, 2723-34	181
1231	Specific interaction of VEGF165 with beta-amyloid, and its protective effect on beta-amyloid-induced neurotoxicity. 2005 , 93, 118-27	30
1230	Emerging treatment approaches for the systemic amyloidoses. 2005 , 68, 1377-90	26

1229	Aluminum chloride does not facilitate deposition of human synthetic amyloid beta1-42 peptide in the rat ventricular system of a short-term infusion model. 2005 , 25, 195-200	2
1228	Age-related changes of intracellular Abeta in cynomolgus monkey brains. 2005 , 31, 170-80	39
1227	Protein drug stability: a formulation challenge. 2005 , 4, 298-306	761
1226	Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. 2005 , 38, 427-37	127
1225	Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. 2005 , 69, 689-98	93
1224	Amyloid-beta aggregates formed at polar-nonpolar interfaces differ from amyloid-beta protofibrils produced in aqueous buffers. 2005 , 67, 164-74	30
1223	Hydrolysis of the amyloid beta-peptide (A beta) 1-40 between Asp23-Val24 produces non-aggregating fragments. An electrospray mass spectrometric study. 2005 , 40, 142-5	7
1222	Fluorescence resonance energy transfer analysis of apolipoprotein E C-terminal domain and amyloid beta peptide (1-42) interaction. 2005 , 80, 877-86	21
1221	Pharmaceutical liquid crystals: the relevance of partially ordered systems. 2005 , 94, 1861-80	66
1220	Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors. 2005 , 6, 628-31	21
1219	Alzheimer's associated inflammation, potential drug targets and future therapies. 2005 , 112, 429-53	82
1218	What is the dominant Abeta species in human brain tissue? A review. 2005 , 7, 29-41	39
1217	Cytokine production by a human microglial cell line: effects of beta-amyloid and alpha-melanocyte-stimulating hormone. 2005 , 8, 267-76	36
1216	An unstructured region is required by GAV homologue for the fibrillization of host proteins. 2005 , 24, 209-18	3
1215	Prediction of "hot spots" of aggregation in disease-linked polypeptides. 2005 , 5, 18	148
1214	Anatomic and Clinical Clues to In Vivo Mechanisms of Amyloidogenesis. 29-46	
1213	Genes involved in Alzheimer's disease, a survey of possible candidates. 2005 , 7, 331-53	29
1212	The role of Abeta peptides in Alzheimer's disease. 2005 , 12, 513-9	21

1211	3D structure of Alzheimer's amyloid-beta(1-42) fibrils. 2005 , 102, 17342-7		1675
1210	Protofibril formation of amyloid beta-protein at low pH via a non-cooperative elongation mechanism. 2005 , 280, 30001-8		96
1209	CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils. 2005 , 280, 8596-605		39
1208	Beyond the signal sequence: protein routing in health and disease. 2005 , 26, 479-503		68
1207	Protein aggregation in Alzheimer's disease and other neuropathological disorders. 2005 , 2, 19-28		30
1206	Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid. 2005 , 280, 30406-15		121
1205	Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site. 2005 , 280, 1007-15		21
1204	Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. 2005 , 280, 2471-80		86
1203	Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40. 2005 , 280, 35069-76		95
1202	Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. 2005 , 2, 36-43		30
1201	A strand-loop-strand structure is a possible intermediate in fibril elongation: long time simulations of amyloid-beta peptide (10-35). 2005 , 127, 15408-16		74
1200	Rapid assembly of amyloid-beta peptide at a liquid/liquid interface produces unstable beta-sheet fibers. <i>Biochemistry</i> , 2005 , 44, 165-73	3.2	39
1199	How proteomics reveals potential biomarkers in brain diseases. 2005 , 2, 901-13		12
1198	Introduction. 2005 , 1-42		1
1197	Transition-state analogue gamma-secretase inhibitors stabilize a 900 kDa presenilin/nicastrin complex. <i>Biochemistry</i> , 2005 , 44, 4332-41	3.2	44
1196	Structural role of glycine in amyloid fibrils formed from transmembrane alpha-helices. <i>Biochemistry</i> , 2005 , 44, 3591-7	3.2	48
1195	Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. 2005 , 19, 1592-601		171
1194	CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. 2005 , 5, 661-72		99

1193	Probing the initial stage of aggregation of the Abeta(10-35)-protein: assessing the propensity for peptide dimerization. 2005 , 345, 1141-56		94
1192	Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils--an in vitro and in vivo electrophysiological study. 2005 , 18, 499-508		24
1191	Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. 2005 , 383, 12-6		72
1190	Abeta-polyacrolein aggregates: novel mechanism of plastic formation in senile plaques. 2005 , 335, 501-4		8
1189	Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. 2005 , 120, 545-55		1439
1188	Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. 2005 , 47, 191-199		463
1187	Thermodynamics of A beta(1-40) amyloid fibril elongation. <i>Biochemistry</i> , 2005 , 44, 12709-18	3.2	196
1186	A rapid label-free electrochemical detection and kinetic study of Alzheimer's amyloid beta aggregation. 2005 , 127, 11892-3		169
1185	Hydrogen-deuterium (H/D) exchange mapping of Abeta 1-40 amyloid fibril secondary structure using nuclear magnetic resonance spectroscopy. <i>Biochemistry</i> , 2005 , 44, 4434-41	3.2	120
1184	Elucidating the Kinetics of Amyloid Fibril Formation. 2005 , 106-118		4
1183	Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. <i>Biochemistry</i> , 2005 , 44, 9871-9	3.2	41
1182	Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. <i>Biochemistry</i> , 2006 , 45, 4727-35	3.2	131
1181	Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?. 2006 , 39, 167-201		325
1180	Conformation-dependent anti-amyloid oligomer antibodies. 2006 , 413, 326-44		128
1179	Alzheimer: 100 Years and Beyond. 2006 ,		5
1178	A short water-soluble self-assembling peptide forms amyloid-like fibrils. 2006 , 4230-2		40
1177	A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. 2006 , 1, 461-9		143
1176	Alzheimer's disease. 2006 , 368, 387-403		2621

1175	Amyloidogenicity and pitrilysin sensitivity of a lysine-free derivative of amyloid beta-peptide cleaved from a recombinant fusion protein. 2006 , 122, 186-97	1
1174	Small molecule oxidation products trigger disease-associated protein misfolding. 2006 , 39, 611-9	92
1173	Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. 2006 , 5, 1010-6	161
1172	On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). <i>Biochemistry</i> , 2006 , 45, 12393-9 3,2	216
1171	Acceleration of alpha-synuclein aggregation by homologous peptides. 2006 , 580, 3657-64	23
1170	Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). 2006 , 106, 1995-2044	1317
1169	Alanine scanning mutagenesis of Abeta(1-40) amyloid fibril stability. 2006 , 357, 1283-94	141
1168	High-resolution atomic force microscopy of soluble Abeta42 oligomers. 2006 , 358, 106-19	188
1167	Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. 2006 , 364, 853-62	214
1166	Fibrillogenic and non-fibrillogenic ensembles of SDS-bound human alpha-synuclein. 2006 , 364, 1061-72	70
1165	Endogenous plastic composite material in the Alzheimer's brain. 2006 , 67, 467-70	2
1164	Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. 2006 , 52, 15-31	257
1163	High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. 2006 , 143, 461-75	146
1162	The nucleation growth and reversibility of Amyloid-beta deposition in vivo. 2006 , 10, 291-301	11
1161	Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. 2006 , 9, 329-39	18
1160	Genetics and pathology of alpha-secretase site AbetaPP mutations in the understanding of Alzheimer's disease. 2006 , 9, 389-98	6
1159	Atomic Force Microscopy. 2006 , 315-334	1
1158	Binding of amyloid beta-peptide to ganglioside micelles is dependent on histidine-13. 2006 , 397, 483-90	78

1157	Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. 2006 , 1, 8	72
1156	Molecular dynamics studies of hexamers of amyloid-beta peptide (16-35) and its mutants: influence of charge states on amyloid formation. 2007 , 66, 575-87	20
1155	Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. 2005 , 15, 72-7	43
1154	The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. 2005 , 15, 84-7	82
1153	Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. 2006 , 16, 40-54	130
1152	A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage. 2006 , 96, 118-25	22
1151	Amyloid precursor protein cross-linking stimulates beta amyloid production and pro-inflammatory cytokine release in monocytic lineage cells. 2006 , 97, 449-61	28
1150	Conserved residues in juxtamembrane region of the extracellular domain of nicastrin are essential for gamma-secretase complex formation. 2006 , 98, 300-9	9
1149	Structure of amyloid beta fragments in aqueous environments. 2006 , 273, 150-8	43
1148	Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer's peptide. Side-chain properties correlate with aggregation propensities. 2006 , 273, 658-68	137
1147	Fifty years of radical ideas. 2000 , 899, 1-14	35
1146	Toward the characterization and identification of gamma-secretases using transition-state analogue inhibitors. 2000 , 920, 197-205	15
1145	Metal chelation as a potential therapy for Alzheimer's disease. 2000 , 920, 292-304	138
1144	Quantitative determination of the topological propensities of amyloidogenic peptides. 2006 , 120, 55-61	8
1143	How to improve guanidinium cations for oxoanion binding in aqueous solution?. 2006 , 250, 3053-3067	178
1142	Search for dual function inhibitors for Alzheimer's disease: synthesis and biological activity of acetylcholinesterase inhibitors of pyridinium-type and their Abeta fibril formation inhibition capacity. 2006 , 14, 472-8	48
1141	Single cell gene expression profiling in Alzheimer's disease. 2006 , 3, 302-18	67
1140	Kinetic analysis of beta-amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing. 2006 , 154, 190-7	52

1139	Ex situ atomic force microscopy analysis of beta-amyloid self-assembly and deposition on a synthetic template. 2006 , 22, 6977-85	27
1138	Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. 2006 , 23, 1407-16	80
1137	Alzheimer's disease: halothane induces Abeta peptide to oligomeric form--solution NMR studies. 2006 , 31, 883-90	24
1136	Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. 2006 , 31, 1153-62	164
1135	Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. 2006 , 111, 430-5	26
1134	Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. 2006 , 112, 163-74	73
1133	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. 2006 , 63, 1538-52	74
1132	The study of Alzheimer's disease biomarkers. 2006 , 2, 5-16	15
1131	Separation and analysis of the soluble trimer of A β 40 and its effects on the rise in intracellular calcium. 2006 , 51, 830-838	3
1130	Alzheimer's disease and post-operative cognitive dysfunction. 2006 , 41, 346-59	132
1129	Development of new screening system for Alzheimer disease, in vitro Abeta sink assay, to identify the dissociation of soluble Abeta from fibrils. 2006 , 22, 487-95	7
1128	Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. 2006 , 23, 433-44	16
1127	Effects of amyloid peptides on A-type K ⁺ currents of Drosophila larval cholinergic neurons. 2006 , 66, 476-87	12
1126	Amyloid beta up-regulates brain-derived neurotrophic factor production from astrocytes: rescue from amyloid beta-related neuritic degeneration. 2006 , 84, 782-9	49
1125	Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. 2006 , 12, 4337-55	36
1124	Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. 2006 , 3, 421-30	111
1123	The role of beta-amyloid protein in synaptic function: implications for Alzheimer's disease therapy. 2006 , 4, 149-63	34
1122	Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems. 2006 , 12, 4295-312	37

1121	gamma-secretase as a therapeutic target for treatment of Alzheimer's disease. 2006 , 12, 661-70	28
1120	Pathways by which Abeta facilitates tau pathology. 2006 , 3, 437-48	148
1119	Molecular and biochemical features in Alzheimer's disease. 2006 , 12, 4389-408	62
1118	Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease. 2006 , 12, 719-38	28
1117	The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. 2006 , 12, 4357-75	54
1116	Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation. 2006 , 20, 331-3	22
1115	Toxicity of recombinant beta-amyloid prefibrillar oligomers on the morphogenesis of the sea urchin <i>Paracentrotus lividus</i> . 2006 , 20, 1916-7	44
1114	Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. 2006 , 281, 24414-22	168
1113	CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. 2006 , 21, 131-8	72
1112	Notice of Concern. 2006 , 58, 135-135	
1111	Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory. 2006 , 317, 334-40	36
1110	The 3D profile method for identifying fibril-forming segments of proteins. 2006 , 103, 4074-8	325
1109	Sporadic cerebral amyloid angiopathy--an important cause of cerebral haemorrhage in older people. 2006 , 35, 565-71	33
1108	Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. 2006 , 66, 1506-10	78
1107	The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Abeta fibril formation without increasing protofibril formation. 2007 , 282, 4916-4923	90
1106	Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. 2007 , 282, 22707-20	86
1105	Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. 2007 , 320, 1144-52	19
1104	Disease modifying approaches for Alzheimer's pathology. 2007 , 13, 1943-54	37

1103	Advances on the understanding of the origins of synaptic pathology in AD. 2007 , 8, 486-508	28
1102	Recent advances in the development of amyloid imaging agents. 2007 , 7, 1773-89	67
1101	Structural and Functional Determinants of gamma-Secretase, an Intramembrane Protease Implicated in Alzheimer's Disease. 2007 , 8, 531-49	21
1100	Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism. 2007 , 7, 687-96	64
1099	Disrupting beta-amyloid aggregation for Alzheimer disease treatment. 2007 , 7, 115-26	143
1098	Development of a novel yeast cell-based system for studying the aggregation of Alzheimer's disease-associated Abeta peptides in vivo. 2007 , 4, 136-47	34
1097	The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. 2007 , 320, 552-8	78
1096	Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity. 2007 , 282, 36987-97	19
1095	Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. 2008 , 143, 475-86	17
1094	Identification of amyloid fibril-forming segments based on structure and residue-based statistical potential. 2007 , 23, 2218-25	86
1093	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. 2007 , 30, 1-32	
1092	The pathogenesis of Alzheimer's disease and the role of Abeta42. 2007 , 12, 4-6	14
1091	Plasma Abeta levels do not reflect brain Abeta levels. 2007 , 66, 264-71	50
1090	Molecular determinants of Alzheimer's disease A β peptide neurotoxicity. 2007 , 2, 397-409	8
1089	Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. 2007 , 28, 537-47	221
1088	Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. 2007 , 6, 4433-9	113
1087	Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. <i>Biochemistry</i> , 2007 , 46, 8850-60	3.2 183
1086	Preferential accumulation of Abeta(1-42) on gel phase domains of lipid bilayers: an AFM and fluorescence study. 2007 , 1768, 146-54	77

1085	A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. 2007 , 1768, 1913-22		26
1084	Methyl dynamics of the amyloid-beta peptides Abeta40 and Abeta42. 2007 , 362, 410-4		29
1083	Abeta40 protects non-toxic Abeta42 monomer from aggregation. 2007 , 369, 909-16		73
1082	Amyloid beta as a regulator of lipid homeostasis. 2007 , 13, 337-44		60
1081	The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. 2007 , 581, 1161-5		64
1080	Abeta Peptide and Alzheimer's Disease. 2007 ,		1
1079	Pharmacological Mechanisms in Alzheimer's Therapeutics. 2007 ,		1
1078	Aspects of beta-amyloid as a biomarker for Alzheimer's disease. 2007 , 1, 59-78		65
1077	Small molecule inhibitors of Abeta assembly. 2007 , 14, 185-97		59
1076	Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. <i>Biochemistry</i> , 2007 , 46, 12451-62	3.2	126
1075	Molecular understanding of Abeta peptide interaction with isoflurane, propofol, and thiopental: NMR spectroscopic study. <i>Biochemistry</i> , 2007 , 46, 762-71	3.2	12
1074	Reconsidering the mechanism of polyglutamine peptide aggregation. <i>Biochemistry</i> , 2007 , 46, 12810-20	3.2	81
1073	An update on the amyloid hypothesis. 2007 , 25, 669-82, vi		34
1072	Role of electrostatic interactions in amyloid beta-protein (A beta) oligomer formation: a discrete molecular dynamics study. 2007 , 92, 4064-77		98
1071	Amyloid peptides and proteins in review. 2007 , 159, 1-77		92
1070	Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. 2007 , 48, 5085-90		53
1069	The Development of Artificial Receptors for Small Peptides Using Combinatorial Approaches. 2007 , 3-30		18
1068	Alzheimer's Disease. 2007 , 779-789		1

1067 References. 329-360

- 1066 Design of peptides that form amyloid-like fibrils capturing amyloid beta1-42 peptides. **2007**, 13, 7745-52 24
- 1065 Sequence-based modeling of Abeta42 soluble oligomers. **2007**, 85, 422-37 5
- 1064 Cleavage agents for soluble oligomers of amyloid beta peptides. **2007**, 46, 7064-7 92
- 1063 Cleavage Agents for Soluble Oligomers of Amyloid β Peptides. **2007**, 119, 7194-7197 19
- 1062 Designed amyloid beta peptide fibril - a tool for high-throughput screening of fibril inhibitors. **2007**, 2, 1613-23 20
- 1061 Differential binding and activation of caspase-3 in cultured hippocampal neurons by assembly forms of A beta 1-42. **2007**, 85, 1205-14 5
- 1060 Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. **2007**, 8, 101-12 3692
- 1059 Intracellular amyloid-beta in Alzheimer's disease. **2007**, 8, 499-509 1474
- 1058 A beta oligomers - a decade of discovery. **2007**, 101, 1172-84 1609
- 1057 Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. **2008**, 104, 524-33 128
- 1056 AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides. **2007**, 8, 65 648
- 1055 Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxy-terminal fragment. **2007**, 25, 427-37 29
- 1054 Multiscale surface self-assembly of an amyloid-like peptide. **2007**, 23, 8150-5 29
- 1053 A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, Abeta, and tau using the amino acid sequence alone. **2007**, 16, 906-18 90
- 1052 Convergent Solid-phase Peptide Synthesis Performed in a CHCl₃-phenol Mixed Solvent: Synthesis of Amyloid β peptides as Examples with a Difficult Sequence. **2007**, 13, 119-128 2
- 1051 Abeta upregulates and colocalizes with LGI3 in cultured rat astrocytes. **2007**, 27, 335-50 13
- 1050 Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. **2007**, 28, 63-71 49

1049	Therapeutics for Alzheimer's disease based on the metal hypothesis. 2008 , 5, 421-32	437
1048	Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. 2008 , 33, 526-32	92
1047	Behavior of neural stem cells in the Alzheimer brain. 2008 , 65, 2372-84	76
1046	Design and characterization of a membrane permeable N-methyl amino acid-containing peptide that inhibits Abeta1-40 fibrillogenesis. 2002 , 60, 37-55	118
1045	Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. 2000 , 75, 1219-33	479
1044	Characterization of the interaction between Abeta 1-42 and glyceraldehyde phosphodehydrogenase. 2008 , 14, 755-62	25
1043	A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's beta-amyloid fibril formation. 2008 , 9, 952-63	43
1042	Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors. 2008 , 3, 120-6	15
1041	pH effects on the conformational preferences of amyloid beta-peptide (1-40) in HFIP aqueous solution by NMR spectroscopy. 2008 , 3, 833-43	15
1040	Localization of the noncovalent binding site between amyloid-beta-peptide and oleuropein using electrospray ionization FT-ICR mass spectrometry. 2008 , 19, 1078-85	32
1039	Inhibition and modulation of gamma-secretase for Alzheimer's disease. 2008 , 5, 391-8	119
1038	Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. 2008 , 22, 162-71	67
1037	Diseases of protein aggregation and the hunt for potential pharmacological agents. 2008 , 3, 165-92	30
1036	Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. 2008 , 5, 225-37	43
1035	Active gamma-secretase is localized to detergent-resistant membranes in human brain. 2008 , 275, 1174-87	72
1034	Lipid-induced conformational transition of the amyloid core fragment Abeta(28-35) and its A30G and A30I mutants. 2008 , 275, 2415-27	11
1033	Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. 2007 , 65, S239-43	29
1032	Abeta-degrading enzymes in Alzheimer's disease. 2008 , 18, 240-52	279

1031	Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. 2008 , 106, 1225-36	58
1030	Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. 2008 , 107, 1634-46	69
1029	Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?. 2008 , 9 Suppl 2, S7	46
1028	Inhibition of LTP in vivo by beta-amyloid peptide in different conformational states. 2008 , 1197, 135-42	25
1027	Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid. 2008 , 175, 209-15	21
1026	The ubiquitin-proteasome system in Alzheimer's disease. 2008 , 12, 363-73	178
1025	Exploitation of HIV protease inhibitor Indinavir as a memory restorative agent in experimental dementia. 2008 , 89, 535-45	37
1024	Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. 2008 , 130, 15437-43	421
1023	Sonication of proteins causes formation of aggregates that resemble amyloid. 2004 , 13, 3017-27	293
1022	Why is the amyloid beta peptide of Alzheimer's disease neurotoxic?. 2008 , 1273-82	106
1021	The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. 2008 , 54, 1617-23	90
1020	Mutations enhance the aggregation propensity of the Alzheimer's A beta peptide. 2008 , 377, 565-74	45
1019	Promotion of amyloid beta protein misfolding and fibrillogenesis by a lipid oxidation product. 2008 , 377, 1236-50	66
1018	Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. 2008 , 384, 450-64	197
1017	Effect on memory of acute administration of naturally secreted fibrils and synthetic amyloid-beta peptides in an invertebrate model. 2008 , 89, 407-18	6
1016	Inhibition of beta-amyloid peptide aggregation and neurotoxicity by alpha-d-mannosylglycerate, a natural extremolyte. 2008 , 29, 578-84	41
1015	Intracerebral hemorrhage. 2009 , 93, 767-90	12
1014	Structural and functional properties of peptides based on the N-terminus of HIV-1 gp41 and the C-terminus of the amyloid-beta protein. 2008 , 1778, 2127-37	16

1013	Abeta peptide interactions with isoflurane, propofol, thiopental and combined thiopental with halothane: a NMR study. 2008 , 1778, 2633-9		17
1012	Detection of Alzheimer's amyloid beta aggregation by capturing molecular trails of individual assemblies. 2008 , 377, 725-728		20
1011	Rapid free energy calculation of peptide self-assembly by REMD umbrella sampling. 2008 , 112, 13493-8		22
1010	Investigation of the mechanism of beta-amyloid fibril formation by kinetic and thermodynamic analyses. 2008 , 24, 5802-8		46
1009	Increasing solubility of proteins and peptides by site-specific modification with betaine. 2008 , 19, 1113-8		36
1008	Water-soluble tripeptide Abeta (9-11) forms amyloid-like fibrils and exhibits neurotoxicity. 2008 , 10, 2625-8		24
1007	Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. <i>Biochemistry</i> , 2008 , 47, 7405-13	3.2	86
1006	Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood. 2008 , 12, 307-20		23
1005	Biological CSF markers of Alzheimer's disease. 2008 , 89, 261-8		8
1004	Amyloid-beta(29-42) dimer formations studied by a multicanonical-multioverlap molecular dynamics simulation. 2008 , 112, 2767-70		42
1003	Comparative molecular dynamics studies of wild-type and oxidized forms of full-length Alzheimer amyloid beta-peptides Abeta(1-40) and Abeta(1-42). 2008 , 112, 7123-31		55
1002	Antibody-catalyzed water-oxidation pathway. 2008 , 80, 1849-1858		3
1001	Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. 2008 , 283, 16790-800		70
1000	Amyloid beta conformation in aqueous environment. 2008 , 5, 540-7		13
999	Protection mechanisms against Abeta42 aggregation. 2008 , 5, 548-54		9
998	Presenilins: members of the gamma-secretase quartets, but part-time soloists too. 2008 , 23, 194-204		96
997	Neprilysin and amyloid beta peptide degradation. 2008 , 5, 225-31		87
996	Processing of amyloid precursor protein and amyloid peptide neurotoxicity. 2008 , 5, 92-9		50

995	The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. 2008 , 283, 28176-89	197
994	Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?. 2008 , 3, 109-11	13
993	Post-translational Chemical Modifications in Amyloid Fibril Formation. 2008 , 81	
992	Alzheimer's disease. 2008 , 199-228	6
991	Drug development based on the metals hypothesis of Alzheimer's disease. 2008 , 15, 223-40	224
990	Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies. 2008 , 4, 140-149	8
989	Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. 2008 , 67, 30-40	17
988	Molecular Aspects of Memory Dysfunction in Alzheimer's Disease. 2008 , 245-293	3
987	nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-beta reverberating on AbetaPP processing. 2009 , 16, 409-19	50
986	Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobe. 2009 , 4, e8492	43
985	Interprotofilament interactions between Alzheimer's Abeta1-42 peptides in amyloid fibrils revealed by cryoEM. 2009 , 106, 4653-8	127
984	The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. 2009 , 284, 22697-702	94
983	Therapy for Alzheimer's Disease: How Effective are Current Treatments?. 2009 , 2, 163-80	69
982	Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide. 2009 , 421, 415-23	354
981	Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. 2009 , 6, 139-47	40
980	The role of adenosine in Alzheimer's disease. 2009 , 7, 207-16	67
979	Cerebral amyloid angiopathy: a common cause of cerebral hemorrhage. 2009 , 16, 2498-513	54
978	Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. 2009 , 10, 1872-95	28

977	Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. 2009 , 29, 4964-71	27
976	A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. 2009 , 66, 190-9	161
975	¹ H NMR analysis of fibril-forming peptide fragments of transthyretin. 1994 , 44, 388-98	26
974	The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid beta-peptide as modeled with N-terminal decapeptide fragments. 1996 , 47, 289-96	24
973	Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. 2009 , 1280, 137-47	48
972	Phenolic oxime oligomers inhibit Alzheimer's amyloid fibril formation and disaggregate fibrils in vitro. 2009 , 10, 1325-9	6
971	Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. 2009 , 29, 295-338	110
970	Protection against amyloid beta cytotoxicity by sulforaphane: role of the proteasome. 2009 , 32, 109-15	59
969	Consumption of grape seed extract prevents amyloid-beta deposition and attenuates inflammation in brain of an Alzheimer's disease mouse. 2009 , 15, 3-14	164
968	Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. 2009 , 66, 2299-318	92
967	A facile method for expression and purification of the Alzheimer's disease-associated amyloid beta-peptide. 2009 , 276, 1266-81	197
966	Aggregation of A beta Alzheimer's disease-related peptide studied by dynamic light scattering. 1998 , 52, 509-17	15
965	Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. 2009 , 110, 697-706	108
964	Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. 2009 , 110, 791-800	43
963	Mechanism of docosahexaenoic acid-induced inhibition of in vitro Abeta1-42 fibrillation and Abeta1-42-induced toxicity in SH-SY5Y cells. 2009 , 111, 568-79	54
962	Molecular dynamics simulation study on conformational behavior of A β (1-40) and A β (1-42) in water and methanol. 2009 , 907, 51-56	5
961	Ca(2+), within the physiological concentrations, selectively accelerates Abeta42 fibril formation and not Abeta40 in vitro. 2009 , 1794, 1537-48	17
960	Poly-N-methylated amyloid beta-peptide (Abeta) C-terminal fragments reduce Abeta toxicity in vitro and in <i>Drosophila melanogaster</i> . 2009 , 52, 8002-9	52

959	Effect of dehydration on the aggregation kinetics of two amyloid peptides. 2009 , 113, 531-5	65
958	Amyloid, The Amyloid β Peptide and Alzheimer's Disease: Structural Considerations. 2009 , 283-304	
957	Side chain interactions can impede amyloid fibril growth: replica exchange simulations of Abeta peptide mutant. 2009 , 113, 11848-57	22
956	Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. 2009 , 106, 18563-8	66
955	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. 2009 , 1792, 482-96	231
954	Effects of docosahexaenoic acid on in vitro amyloid beta peptide 25-35 fibrillation. 2009 , 1791, 289-96	30
953	Design and biological activity of beta-sheet breaker peptide conjugates. 2009 , 380, 397-401	39
952	Mutations in amyloid precursor protein affect its interactions with presenilin/gamma-secretase. 2009 , 41, 166-74	43
951	The structure of Abeta42 C-terminal fragments probed by a combined experimental and theoretical study. 2009 , 387, 492-501	75
950	[[111C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. 2009 , 54, 347-57	72
949	Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. 2009 , 55, 243-52	54
948	Oligomeric aggregates of amyloid beta peptide 1-42 activate ERK/MAPK in SH-SY5Y cells via the alpha7 nicotinic receptor. 2009 , 55, 796-801	38
947	The chemistry of Alzheimer's disease. 2009 , 38, 2698-715	339
946	Inhibition of beta-amyloid(1-40) Peptide Aggregation and Neurotoxicity by Citrate. 2009 , 13, 273-9	2
945	Branching in amyloid fibril growth. 2009 , 96, 1529-36	120
944	On the stability of the soluble amyloid aggregates. 2009 , 97, 1454-60	37
943	Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. 2009 , 29, 9321-9	164
942	Punching Holes in Membranes: How Oligomeric Pore-Forming Proteins and Lipids Cooperate to Form Aqueous Channels in Membranes. 2009 , 223-262	4

941	The molecular and cellular pathogenesis of dementia of the Alzheimer's type an overview. 2009 , 84, 151-65		18
940	Chapter 4 - Applications of nanotechnology in molecular imaging of the brain. 2009 , 180, 72-96		8
939	Secretase inhibitors and modulators for Alzheimer's disease treatment. 2009 , 9, 661-79		110
938	Simulations of nucleation and elongation of amyloid fibrils. 2009 , 130, 035102		99
937	An improved screening model to identify inhibitors targeting zinc-enhanced amyloid aggregation. 2009 , 81, 6944-51		7
936	The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. 2009 , 17, 33-47		56
935	Probing the effect of amino-terminal truncation for Abeta1-40 peptides. 2009 , 113, 6692-702		40
934	Overcoming synthetic Abeta peptide aging: a new approach to an age-old problem. 2009 , 16, 71-80		33
933	Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide. 2009 , 6228-30		36
932	Aggregation Behavior of Amyloid β 2Peptide Studied Using 55 MHz Wireless Electrodeless Quartz Crystal Microbalance. 2009 , 48, 07GF01		8
931	Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. 2009 , 15, 358-74		113
930	In silico study of full-length amyloid beta 1-42 tri- and penta-oligomers in solution. 2009 , 113, 11710-9		79
929	Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain. 2009 , 16, 211-24		57
928	Analytical Tools for Detecting Amyloid Beta Oligomerisation and Assembly. 2009 , 5, 229-245		10
927	Preparation and characterization of neurotoxic tau oligomers. <i>Biochemistry</i> , 2010 , 49, 10039-41	3.2	254
926	Separation and characterization of aggregated species of amyloid-beta peptides. 2010 , 397, 2357-66		9
925	Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. 2010 , 39, 877-88		44
924	Stability of A β (1-42) peptide fibrils as consequence of environmental modifications. 2010 , 39, 1613-23		17

923	Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation. 2010 , 18, 222-8	26
922	Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology. 2010 , 119, 543-54	55
921	Exploration of the mechanism for LPFFD inhibiting the formation of beta-sheet conformation of A beta(1-42) in water. 2010 , 16, 813-21	42
920	Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. 2010 , 38, 104-15	30
919	The transition metals copper and iron in neurodegenerative diseases. 2010 , 186, 184-99	171
918	Role of Metals in Alzheimer Disease. 2010 , 543-558	1
917	Role of Oxidatively Stressed Lipids in Amyloid Formation and Toxicity. 2010 , 585-614	
916	Controlling amyloid-beta peptide(1-42) oligomerization and toxicity by fluorinated nanoparticles. 2010 , 11, 1905-13	39
915	Adult hippocampal neurogenesis in aging and Alzheimer's disease. 2010 , 90, 284-96	40
914	Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS. 2010 , 21, 1506-14	26
913	Docosahexaenoic acid supplementation of primary rat hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid beta protein(42) and up-regulates cytoskeletal protein expression. 2010 , 21, 345-50	22
912	Novel Notch-sparing gamma-secretase inhibitors derived from a peroxisome proliferator-activated receptor agonist library. 2010 , 20, 5282-5	5
911	Optimization protocol for amyloid-beta peptides detection in human cerebrospinal fluid using SELDI TOF MS. 2010 , 4, 352-7	26
910	A method to prevent cross contamination during 2-DE by beta amyloid peptides. 2010 , 10, 3539-43	1
909	Comparing the folding free-energy landscapes of Abeta42 variants with different aggregation properties. 2010 , 78, 2600-8	42
908	Despite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicity. 2010 , 113, 1252-62	32
907	Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. 2010 , 17, 561-7	826
906	The PSEN1 I143T mutation in a Swedish family with Alzheimer's disease: clinical report and quantification of A beta in different brain regions. 2010 , 18, 1202-8	25

905	Alzheimer's disease: strategies for disease modification. 2010 , 9, 387-98	808
904	Anesthetics promoting in vitro A β P metabolism and amyloid- β toxicity. 2010 , 22 Suppl 3, 21-6	2
903	Early amyloid accumulation in the hippocampus of SAMP8 mice. 2010 , 19, 1303-15	104
902	High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. 2010 , 24, 2716-26	196
901	Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. 2010 , 30, 7281-9	356
900	The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. 2010 , 24, 916-30	34
899	Distribution of neprilysin and deposit patterns of Abeta subtypes in the brains of aged squirrel monkeys (<i>Saimiri sciureus</i>). 2010 , 17, 75-82	26
898	Amyloid- β as a modulator of synaptic plasticity. 2010 , 22, 741-63	170
897	AFFITOME β technology in neurodegenerative diseases: the doubling advantage. 2010 , 6, 948-52	36
896	Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's A β peptide and reduce its cytotoxicity. 2010 , 132, 17015-22	69
895	Electric Field Effects on Short Fibrils of A β Amyloid Peptides. 2010 , 6, 3516-26	29
894	Therapeutic versus neuroinflammatory effects of passive immunization is dependent on A β amyloid burden in a transgenic mouse model of Alzheimer's disease. 2010 , 7, 57	15
893	Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. 2010 , 1207, 58-70	48
892	Development of a proteolytically stable retro-inverso peptide inhibitor of beta-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. <i>Biochemistry</i> , 2010 , 49, 3261-72 ^{3,2}	120
891	Effects of peptides derived from terminal modifications of the a β central hydrophobic core on a β fibrillization. 2010 , 1, 661-78	27
890	A direct determination of the dissociation constant for the Cu(II) complex of amyloid beta 1-40 peptide. 2010 , 23, 336-40	51
889	The Cu(II)/Abeta/human serum albumin model of control mechanism for copper-related amyloid neurotoxicity. 2010 , 23, 298-308	40
888	Guanidinium Based Anion Receptors. 2010 , 273-317	2

887	Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity. <i>Biochemistry</i> , 2010 , 49, 3254-60	3-2	39
886	Label-free high-throughput screening assay for inhibitors of Alzheimer's amyloid- β peptide aggregation based on MALDI MS. 2010 , 82, 8558-65		28
885	Micelle-like architecture of the monomer ensemble of Alzheimer's amyloid- β peptide in aqueous solution and its implications for A β aggregation. 2010 , 403, 148-165		66
884	The extracellular domain of Bri2 (ITM2B) binds the ABri peptide (1-23) and amyloid beta-peptide (Abeta1-40): Implications for Bri2 effects on processing of amyloid precursor protein and Abeta aggregation. 2010 , 393, 356-61		40
883	Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. 2010 , 6, 131-44		1328
882	REVIEW: Curcumin and Alzheimer's disease. 2010 , 16, 285-97		295
881	Targeting Abeta and tau in Alzheimer's disease, an early interim report. 2010 , 223, 252-66		68
880	Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention. 2010 , 223, 311-21		92
879	Signaling effect of amyloid-beta(42) on the processing of AbetaPP. 2010 , 221, 18-25		46
878	Transmembrane structures for Alzheimer's A β (1-42) oligomers. 2010 , 132, 13300-12		116
877	The secretases: enzymes with therapeutic potential in Alzheimer disease. 2010 , 6, 99-107		585
876	[The role of cyclooxygenases in neurotoxicity of amyloid beta peptides in Alzheimer's disease]. 2010 , 44, 65-79		4
875	A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. 2010 , 2, 7		77
874	Evaluation of A β fibrillization inhibitory effect by a PEG-peptide conjugate based on an A β peptide fragment with intramolecular FRET. 2011 , 47, 4709-11		6
873	Copper inducing A β 2 rather than A β 0 nanoscale oligomer formation is the key process for A β neurotoxicity. 2011 , 3, 4746-51		23
872	Dissociation between the processivity and total activity of γ -secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations. <i>Biochemistry</i> , 2011 , 50, 9023-35	3-2	87
871	Seed-dependent deposition behavior of A β peptides studied with wireless quartz-crystal-microbalance biosensor. 2011 , 83, 4982-8		19
870	A β 0 and A β 2 amyloid fibrils exhibit distinct molecular recycling properties. 2011 , 133, 6505-8		79

869	Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable β -Secretase Modulator. 2011 , 2, 786-91	24
868	Distinct effects of Zn ²⁺ , Cu ²⁺ , Fe ³⁺ , and Al ³⁺ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation. 2011 , 286, 9646-56	144
867	Mutations that replace aromatic side chains promote aggregation of the Alzheimer's A β peptide. <i>Biochemistry</i> , 2011 , 50, 4058-67	3.2 51
866	Reward and autoreceptors. 2011 , 14, 950	
865	Atomic-resolution dynamics on the surface of amyloid- β protofibrils probed by solution NMR. 2011 , 480, 268-72	320
864	What drives amyloid molecules to assemble into oligomers and fibrils?. 2011 , 100, 450-8	107
863	Alzheimer's disease drug candidates stabilize A- β protein native structure by interacting with the hydrophobic core. 2011 , 100, 1076-82	27
862	Effect of zinc binding on β amyloid structure and dynamics: implications for A β aggregation. 2011 , 101, 1202-11	72
861	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. 2011 , 15, 83-102	24
860	Chapter 6: The Inorganic Side of Alzheimer's Disease. 2011 , 112-140	1
859	Dynamics of A β 2 reduction in plasma, CSF and brain of rats treated with the β -secretase modulator, GSM-10h. 2011 , 8, 455-64	29
858	A kinetic aggregation assay allowing selective and sensitive amyloid- β quantification in cells and tissues. <i>Biochemistry</i> , 2011 , 50, 1607-17	3.2 29
857	β -Secretase Inhibition: An Overview of Development of Inhibitors for the Treatment of Alzheimer's Disease. 2011 , 353-390	
856	Protein Folding and Solubility: Pathways and High-Throughput Assays. 2011 , 121-145	
855	Submicromolar A β 2 reduces hippocampal glutamate receptors and presynaptic markers in an aggregation-dependent manner. 2011 , 1812, 1664-74	16
854	Secretases as therapeutic targets for Alzheimer's disease. 2011 , 404, 10-5	18
853	Structural basis for A β 2 toxicity inhibition by AIC-terminal fragments: discrete molecular dynamics study. 2011 , 410, 316-28	43
852	Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model. 2011 , 29, 6252-8	17

- 851 Tau Oligomers as Potential Drug Target for Alzheimer Disease (AD) Treatment. **2011**,
- 850 Alzheimer's Diseases: Towards Biomarkers for an Early Diagnosis. **2011**,
- 849 Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. **2010**, 2011, 548380 61
- 848 Effect of surfaces on amyloid fibril formation. **2011**, 6, e25954 117
- 847 Novel A β isoforms in Alzheimer's disease - their role in diagnosis and treatment. **2011**, 17, 2594-602 60
- 846 Aggregation state and neurotoxic properties of Alzheimer's β amyloid peptide. **2011**, 12, 235-57 14
- 845 A β -degrading enzymes: potential for treatment of Alzheimer disease. **2011**, 70, 944-59 185
- 844 [108th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Progress in dementia research--dementia disorders and protein; (2) amyloid P3 protein]. **2011**, 100, 2469-75
- 843 Low-n oligomers as therapeutic targets of Alzheimer's disease. **2011**, 117, 19-28 65
- 842 γ -Secretase complexes containing caspase-cleaved presenilin-1 increase intracellular A β (42)/A β (40) ratio. **2011**, 15, 2150-63 6
- 841 Recent progress in understanding Alzheimer's β amyloid structures. **2011**, 36, 338-45 129
- 840 Structural preferences of A β fragments in different micellar environments. **2011**, 45, 369-76 10
- 839 Inflammation in the early stages of neurodegenerative pathology. **2011**, 238, 1-11 160
- 838 Solid-state NMR analysis of interaction sites of curcumin and 42-residue amyloid β protein fibrils. **2011**, 19, 5967-74 73
- 837 Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein. **2011**, 1387, 141-8 39
- 836 Potent amyloidogenicity and pathogenicity of A β 3. **2011**, 14, 1023-32 206
- 835 Local Surface Plasmon Resonance and Electrochemical Biosensing Systems for Analyzing Functional Peptides. **2011**, 211-223
- 834 Inhibition of aggregation of amyloid peptides by beta-sheet breaker peptides and their binding affinity. **2011**, 115, 7433-46 143

833	Alzheimer's disease: the challenge of the second century. 2011 , 3, 77sr1	893
832	Different CSF β amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. 2011 , 118, 691-7	15
831	APP transgenic mice: their use and limitations. 2011 , 13, 117-37	54
830	Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation. 2011 , 6, 15	16
829	APP processing in Alzheimer's disease. 2011 , 4, 3	479
828	Differences in cytotoxicity of β sheet peptides originated from silk and amyloid β . 2011 , 11, 60-4	24
827	Synaptic failure and adenosine triphosphate imbalance induced by amyloid- β aggregates are prevented by blueberry-enriched polyphenols extract. 2011 , 89, 1499-508	35
826	The use of mass spectrometry to study amyloid- β peptides. 2011 , 30, 347-65	37
825	Studies of the growth, evolution, and self-aggregation of β amyloid fibrils using tapping-mode atomic force microscopy. 2011 , 74, 699-708	18
824	Characterizing amyloid-beta protein misfolding from molecular dynamics simulations with explicit water. 2011 , 32, 349-55	69
823	Structural and mechanistic commonalities of amyloid- β and the prion protein. 2011 , 5, 126-37	22
822	Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease. 2011 , 6, 222-33	16
821	A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease. 2011 , 24, 743-50	79
820	Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. 2011 , 26, 54-69	98
819	Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid. 2011 , 286, 33747-58	48
818	Parkin mediates beclin-dependent autophagic clearance of defective mitochondria and ubiquitinated A β in AD models. 2011 , 20, 2091-102	132
817	Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. 2011 , 286, 27081-91	53
816	Amyloid β and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. 2011 , 49, 367-74	51

815	Intracerebral Hemorrhage. 2011 , 531-588	
814	An overlooked neurotoxic species in Alzheimer's disease. 2011 , 14, 949-50	12
813	Neuroactive Multifunctional Tacrine Congeners with Cholinesterase, Anti-Amyloid Aggregation and Neuroprotective Properties. 2011 , 4, 382-418	47
812	Kinetics of amyloid aggregation: a study of the GNNQQNY prion sequence. 2012 , 8, e1002782	35
811	The mechanism of β -Secretase dysfunction in familial Alzheimer disease. 2012 , 31, 2261-74	357
810	Identification of novel β -secretase-associated proteins in detergent-resistant membranes from brain. 2012 , 287, 11991-2005	39
809	Discovery and structure activity relationship of small molecule inhibitors of toxic β amyloid-42 fibril formation. 2012 , 287, 34786-800	44
808	Development of a magnetic immunosorbent for on-chip preconcentration of amyloid β isoforms: Representatives of Alzheimer's disease biomarkers. 2012 , 6, 24126-2412612	25
807	β sheet propensity controls the kinetic pathways and morphologies of seeded peptide aggregation. 2012 , 137, 145104	25
806	Differential effects between β -secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. 2012 , 32, 2037-50	155
805	Promiscuous cross-seeding between bacterial amyloids promotes interspecies biofilms. 2012 , 287, 35092-351084	
804	PSEN1 mutation carriers present lower cerebrospinal fluid amyloid- β 2 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers. 2012 , 30, 605-16	6
803	Alzheimer's disease amyloid peptides interact with DNA, as proved by surface plasmon resonance. 2012 , 9, 924-34	12
802	β -Secretase modulator in Alzheimer's disease: shifting the end. 2012 , 31, 685-96	29
801	Abligomer toxicity inhibitor protects memory in models of synaptic toxicity. 2012 , 167, 383-92	12
800	A comparative analysis of the aggregation behavior of amyloid- β peptide variants. 2012 , 586, 4088-93	52
799	Copper and oxidative stress in the pathogenesis of Alzheimer's disease. <i>Biochemistry</i> , 2012 , 51, 6289-3113.2	202
798	Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome. 2012 , 43, 645-54	42

797	Discovery of SCH 900229, a Potent Presenilin 1 Selective β -Secretase Inhibitor for the Treatment of Alzheimer's Disease. 2012 , 3, 892-6	8
796	Facile methodology for monitoring amyloid- β fibrillization. 2012 , 3, 896-9	8
795	Detailed analysis of the energy barriers for amyloid fibril growth. 2012 , 51, 5247-51	88
794	The MAPT H1 haplotype is associated with tangle-predominant dementia. 2012 , 124, 693-704	54
793	APP mutations in the A β -coding region are associated with abundant cerebral deposition of A β 8. 2012 , 124, 809-21	29
792	Expression in drosophila of tandem amyloid β peptides provides insights into links between aggregation and neurotoxicity. 2012 , 287, 20748-54	34
791	Examining the mechanisms that link β amyloid and β synuclein pathologies. 2012 , 4, 11	67
790	A peptide probe for detection of various beta-amyloid oligomers. 2012 , 8, 2741-52	14
789	The genetics of Alzheimer disease. 2012 , 2,	431
788	Bifunctional compounds for controlling metal-mediated aggregation of the $\alpha\beta$ peptide. 2012 , 134, 6625-36	163
787	Fluid biomarkers in Alzheimer disease. 2012 , 2, a006221	120
786	Interaction between NH(2)-tau fragment and A β in Alzheimer's disease mitochondria contributes to the synaptic deterioration. 2012 , 33, 833.e1-25	59
785	Amyloid- β oligomers stimulate microglia through a tyrosine kinase dependent mechanism. 2012 , 33, 2247-61	69
784	Distinguishing crystal-like amyloid fibrils and glass-like amorphous aggregates from their kinetics of formation. 2012 , 109, 14446-51	200
783	The toxic A β oligomer and Alzheimer's disease: an emperor in need of clothes. 2012 , 15, 349-57	1386
782	Label-free electrochemical detection of Amyloid beta aggregation in the presence of iron, copper and zinc. 2012 , 681, 89-95	38
781	Oligomeric amyloid- β peptide affects the expression of genes involved in steroid and lipid metabolism in primary neurons. 2012 , 61, 321-33	15
780	Studies of protein aggregation in A53T β synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. 2012 , 507, 137-42	5

779	Peptide-surfactant interactions: consequences for the amyloid-beta structure. 2012 , 420, 136-40	19
778	Utilization of a multiple antigenic peptide as a calibration standard in the BAN50 single antibody sandwich ELISA for A β oligomers. 2012 , 422, 375-80	9
777	Negatively charged gold nanoparticles inhibit Alzheimer's amyloid- β fibrillization, induce fibril dissociation, and mitigate neurotoxicity. 2012 , 8, 3631-9	223
776	Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates. 2012 , 19, 104	38
775	Alzheimer's disease and the amyloid β protein. 2012 , 107, 101-24	96
774	N-Terminal pyroglutamate formation of A β 8 and A β 0 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. 2012 , 121, 774-84	68
773	Native structure protects SUMO proteins from aggregation into amyloid fibrils. 2012 , 13, 1916-26	26
772	Solid-state NMR analysis of the β strand orientation of the protofibrils of amyloid β protein. 2012 , 428, 458-62	14
771	Investigating how peptide length and a pathogenic mutation modify the structural ensemble of amyloid beta monomer. 2012 , 102, 315-24	98
770	Parkin prevents cortical atrophy and A β -induced alterations of brain metabolism: ^{13}C NMR and magnetic resonance imaging studies in AD models. 2012 , 225, 22-34	17
769	Evidence for the accumulation of A β immunoreactive material in the human brain and in transgenic animal models. 2012 , 91, 1141-7	11
768	Synaptic dysfunction in Alzheimer's disease. 2012 , 970, 573-601	79
767	β Synuclein aggregation and modulating factors. 2012 , 65, 109-64	21
766	The molecular pathology of Alzheimer's disease. 2012 , 22, 11-22, vii	40
765	Structures and free energy landscapes of aqueous zinc(II)-bound amyloid- β (1-40) and zinc(II)-bound amyloid- β (1-42) with dynamics. 2012 , 17, 927-38	32
764	Synaptic silencing and plasma membrane dyshomeostasis induced by amyloid- β peptide are prevented by <i>Aristotelia chilensis</i> enriched extract. 2012 , 31, 879-89	29
763	Methods for analysis of amyloid- β aggregates. 2012 , 28, 735-58	47
762	Isolated amyloid- β (1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. 2012 , 3, 302-11	47

761	Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. 2012 , 2, 700	305
760	Dimer formation enhances structural differences between amyloid β protein (1-40) and (1-42): an explicit-solvent molecular dynamics study. 2012 , 7, e34345	88
759	β -Secretase-Dependent Proteolysis of Transmembrane Domain of Amyloid Precursor Protein: Successive Tri- and Tetrapeptide Release in Amyloid β Protein Production. 2012 , 2012, 591392	23
758	Modulation of gamma-secretase for the treatment of Alzheimer's disease. 2012 , 2012, 210756	21
757	Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases. 2012 , 2012, 345472	24
756	Microglial Amyloid- β -40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease. 2012 , 2012, 685739	32
755	Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. 2012 , 17, 2024-34	31
754	Mechanisms of Amyloid- β Peptide Clearance: Potential Therapeutic Targets for Alzheimer's Disease. 2012 , 20, 245-55	89
753	Calpain dysregulation in Alzheimer's disease. 2012 , 2012, 728571	32
752	Alzheimer's disease and related dementias. 17-31	
751	Amyloid- β and the failure to form mitochondrial cristae: a biomimetic study involving artificial membranes. 2012 , 28, 33-48	9
750	The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. 2012 , 112, 5147-92	636
749	The genetics and neuropathology of Alzheimer's disease. 2012 , 124, 305-23	174
748	Analyse der Energiebarrieren für das Wachstum von Amyloidfibrillen. 2012 , 124, 5339-5344	4
747	Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms. 2012 , 7, 359-74	52
746	The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. 2012 , 60, 251-66	257
745	A β toxicity in Alzheimer's disease. 2012 , 45, 366-78	110
744	A β potentiates inflammatory activation of glial cells induced by scavenger receptor ligands and inflammatory mediators in culture. 2012 , 22, 69-78	26

743	Proteolytic processing of Alzheimer's Amyloid precursor protein. 2012 , 120 Suppl 1, 9-21	208
742	Copper(II) interaction with amyloid- β Affinity and speciation. 2012 , 256, 3-12	62
741	Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models. 2012 , 235, 297-305	30
740	Somatostatin receptor subtype-4 agonist NNC 26-9100 decreases extracellular and intracellular A β trimers. 2012 , 683, 116-24	27
739	Modulation of fibril formation by a beta-sheet breaker peptide ligand: an electrochemical approach. 2012 , 84, 49-52	28
738	Insulin signaling, glucose metabolism and mitochondria: major players in Alzheimer's disease and diabetes interrelation. 2012 , 1441, 64-78	136
737	Kinetics of peptide secondary structure conversion during amyloid β protein fibrillogenesis. 2012 , 301, 95-102	12
736	Vitamin A and Alzheimer's disease. 2012 , 12, 180-8	63
735	Exploring the binding mechanism of thioflavin-T to the Amyloid peptide by blind docking method. 2012 , 55, 112-117	12
734	Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models. 2013 , 5, 19	23
733	Amyloid beta β 1A β up-regulates the expression of sortilin via the p75(NTR)/RhoA signaling pathway. 2013 , 127, 152-62	32
732	The development of an in vivo β -secretase assay using zebrafish embryos. 2013 , 36, 521-34	9
731	Hamiltonian replica-permutation method and its applications to an alanine dipeptide and amyloid-(29-42) peptides. 2013 , 34, 2493-7	45
730	Alzheimer's disease: identification and development of β -secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS). 2013 , 8, 1041-56	13
729	Amyloid β peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. 2013 , 19, 823-35	347
728	Amyloid-(1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. 2013 , 8, 312-22	22
727	Structural heterogeneity in familial Alzheimer's disease mutants of amyloid-beta peptides. 2013 , 9, 997-1003	32
726	The early changes in behavior and the myelinated fibers of the white matter in the Tg2576 transgenic mouse model of Alzheimer's disease. 2013 , 555, 112-7	4

725	Interaction between soluble A β (1-40) monomer and A β (1-42) fibrils probed by paramagnetic relaxation enhancement. 2013 , 587, 620-4	5
724	Amyloid β precursor protein as a molecular target for amyloid β induced neuronal degeneration in Alzheimer's disease. 2013 , 34, 2525-37	33
723	Amyloid fibril formation by a normally folded protein in the absence of denaturants and agitation. 2013 , 20, 226-32	5
722	Direct observation of amyloid nucleation under nanomechanical stretching. 2013 , 7, 7734-43	18
721	Selenoprotein P and selenoprotein M block Zn ²⁺ -mediated A β 2 aggregation and toxicity. 2013 , 5, 861-70	39
720	Topology and structural self-organization in folded proteins. 2013 , 88, 042709	11
719	The inhibitory effects of Escherichia coli maltose binding protein on β amyloid aggregation and cytotoxicity. 2013 , 538, 41-8	7
718	Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. 2013 , 65, 1773-84	93
717	SUMO and Alzheimer's disease. 2013 , 15, 720-36	56
716	Molecular structure of β amyloid fibrils in Alzheimer's disease brain tissue. 2013 , 154, 1257-68	808
715	Shotgun brain proteomics reveals early molecular signature in presymptomatic mouse model of Alzheimer's disease. 2013 , 37, 297-308	14
714	Kinetic studies of inhibition of the amyloid beta (1-42) aggregation using a ferrocene-tagged β sheet breaker peptide. 2013 , 434, 292-9	23
713	The β -secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl)amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates A β 1-42 seeding and short-term memory deficits in the A β 5-35 mouse model of Alzheimer's disease. 2013 , 698, 193-9	28
712	Critique of the use of fluorescence-based reporters in Escherichia coli as a screening tool for the identification of peptide inhibitors of A β 2 aggregation. 2013 , 19, 74-83	4
711	Stability of early-stage amyloid- β (1-42) aggregation species. 2013 , 1834, 65-70	14
710	C-terminal turn stability determines assembly differences between A β 0 and A β 2. 2013 , 425, 292-308	66
709	Structure activity relationship studies of tricyclic bispyran sulfone β -secretase inhibitors. 2013 , 23, 844-9	10
708	Toward the structure of presenilin/ β -secretase and presenilin homologs. 2013 , 1828, 2886-97	33

707	Stable conformation of full-length amyloid- β (1-42) monomer in water: Replica exchange molecular dynamics and ab initio molecular orbital simulations. 2013 , 577, 131-137	15
706	Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid β protein. 2013 , 425, 2260-75	42
705	The structures of the E22Q mutant-type amyloid- β alloforms and the impact of E22Q mutation on the structures of the wild-type amyloid- β alloforms. 2013 , 4, 310-20	34
704	Triazolopyrimidinones as β -secretase modulators: structure-activity relationship, modulator profile, and in vivo profiling. 2013 , 4, 422	9
703	Comparative studies of disordered proteins with similar sequences: application to A β 40 and A β 42. 2013 , 104, 1546-55	30
702	Spike bursts increase amyloid- β 40/42 ratio by inducing a presenilin-1 conformational change. 2013 , 16, 587-95	66
701	From Disordered Amyloid β Proteins to Soluble Oligomers and Protofibrils Using Discrete Molecular Dynamics. 2013 , 333-357	
700	In silico investigation and targeting of amyloid β oligomers of different size. 2013 , 9, 2118-24	16
699	Proposal for an inhibitor of Alzheimer's disease blocking aggregation of amyloid- β peptides:ab initiomolecular simulations. 2013 , 433, 012033	1
698	Differences in β strand populations of monomeric A β 40 and A β 42. 2013 , 104, 2714-24	114
697	Reconsider Alzheimer's disease by the 'calpain-cathepsin hypothesis'--a perspective review. 2013 , 105, 1-23	70
696	Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics. 2013 , 440, 56-62	40
695	Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. 2013 , 72, 291-300	120
694	How the amyloid- β peptide and membranes affect each other: an extensive simulation study. 2013 , 1828, 327-39	55
693	Acceleration of deposition of A β (1-40) peptide on ultrasonically formed A β (1-42) nucleus studied by wireless quartz-crystal-microbalance biosensor. 2013 , 40, 200-5	8
692	Tracking the mechanism of fibril assembly by simulated two-dimensional ultraviolet spectroscopy. 2013 , 117, 342-50	11
691	β -Secretase inhibitors and modulators. 2013 , 1828, 2898-907	190
690	Introduction. 2013 , 1-42	

689	Assessing the causes and consequences of co-polymerization in amyloid formation. 2013 , 7, 359-68	37
688	The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease. 2013 , 2013, 814390	54
687	Infectivity versus Seeding in Neurodegenerative Diseases Sharing a Prion-Like Mechanism. 2013 , 2013, 583498	18
686	Thermodynamically stable amyloid- β monomers have much lower membrane affinity than the small oligomers. 2013 , 4, 84	44
685	Steroids as β -secretase modulators. 2013 , 27, 3775-85	32
684	Pulsed hydrogen-deuterium exchange mass spectrometry probes conformational changes in amyloid beta (A β) peptide aggregation. 2013 , 110, 14604-9	83
683	Amyloid fibrils composed of hexameric peptides attenuate neuroinflammation. 2013 , 5, 179ra42	53
682	β -Secretase β -Regulated Signaling and Alzheimer's Disease. 2013 ,	
681	Wireless-electrodeless quartz-crystal-microbalance biosensors for studying interactions among biomolecules: a review. 2013 , 89, 401-17	46
680	The genetics of dementia. 2013 , 33, 417-22	3
679	Initial stages of beta-amyloid A β and A β oligomerization observed using fluorescence decay and molecular dynamics analyses of tyrosine. 2013 , 1, 015006	16
678	Coulomb replica-exchange method: handling electrostatic attractive and repulsive forces for biomolecules. 2013 , 34, 622-39	21
677	Structural biology of presenilins and signal peptide peptidases. 2013 , 288, 14673-80	36
676	Shuttling protein nucleolin is a microglia receptor for amyloid beta peptide 1-42. 2013 , 36, 1587-93	10
675	Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from A β 2 induced cytotoxicity. 2013 , 3, 2702	19
674	Cerebrospinal fluid a β to tau ratio and postoperative cognitive change. 2013 , 258, 364-9	49
673	Approaches to a multitargeting drug development: first profiled 3-ethoxycarbonyl-1-aza-9-oxafluorenes representing a perspective compound class targeting Alzheimer disease relevant kinases CDK1, CDK5 and GSK-3 β 2014 , 10, 90-7	3
672	BACE1: Expression, Regulation, and Therapeutic Potential of the Major Alzheimer's Disease Beta-Secretase. 2013 , 9, 3-14	2

671	The pathogenic $\alpha\beta$ 3 is enriched in familial and sporadic Alzheimer disease. 2013 , 8, e55847	54
670	A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. 2013 , 8, e67898	43
669	Binding, conformational transition and dimerization of amyloid- β peptide on GM1-containing ternary membrane: insights from molecular dynamics simulation. 2013 , 8, e71308	46
668	A microliter-scale high-throughput screening system with quantum-dot nanoprobe for amyloid- β aggregation inhibitors. 2013 , 8, e72992	22
667	Stability of transmembrane amyloid β peptide and membrane integrity tested by molecular modeling of site-specific A β 2 mutations. 2013 , 8, e78399	26
666	Therapeutic Targets in the Ubiquitin-proteasome System for Alzheimer's Disease. 2013 , 9, 46-54	1
665	Self-propagative replication of A β oligomers suggests potential transmissibility in Alzheimer disease. 2014 , 9, e111492	19
664	Independent relationship between amyloid precursor protein (APP) dimerization and β -secretase processivity. 2014 , 9, e111553	22
663	Feasibility of β sheet breaker peptide-H102 treatment for Alzheimer's disease based on β amyloid hypothesis. 2014 , 9, e112052	21
662	Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. 2014 , 6, 32	58
661	Helicobacter pylori filtrate impairs spatial learning and memory in rats and increases β amyloid by enhancing expression of presenilin-2. 2014 , 6, 66	44
660	A β degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. 2014 , 6, 238	34
659	Alzheimer Disease: The Role of A β in the Glutamatergic System. 2014 ,	6
658	Accumulation of Abnormally Processed Tau Protein in Neuronal Cells as a Biomarker for Dementia. 2014 ,	
657	Novel insights into amylin aggregation. 2014 , 28, 123-135	0
656	The AgrD N-terminal leader peptide of Staphylococcus aureus has cytolytic and amyloidogenic properties. 2014 , 82, 3837-44	24
655	β -Secretase processing and effects of β -secretase inhibitors and modulators on long A β peptides in cells. 2014 , 289, 3276-87	21
654	Clearing the amyloid in Alzheimer's: progress towards earlier diagnosis and effective treatments - an update for clinicians. 2014 , 4, 363-78	15

653	Atomistic characterization of binding modes and affinity of peptide inhibitors to amyloid- β protein. 2014 , 8, 433-444		12
652	Senile plaques and cerebral amyloid angiopathy in an aged California sea lion (<i>Zalophus californianus</i>). 2014 , 21, 211-5		5
651	Metabolomics in the Study of Alzheimer's Disease. 2014 , 64, 249-278		1
650	An effective treatment for Alzheimer's disease must consider both amyloid and tau. 2014 , 7, hzu002-hzu002		22
649	Structure of N-terminal sequence Asp-Ala-Glu-Phe-Arg-His-Asp-Ser of A β peptide with phospholipase A2 from venom of Andaman Cobra sub-species <i>Naja naja sagittifera</i> at 2.0 Å resolution. 2014 , 15, 4221-36		1
648	Brain alterations and clinical symptoms of dementia in diabetes: a β tau-dependent and independent mechanisms. 2014 , 5, 143		33
647	Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. 2014 , 10, e1003956		105
646	Unlocking truths of β -secretase in Alzheimer's disease: what is the translational potential?. 2014 , 9, 419-429		11
645	Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type. 2014 , 25, 641-51		20
644	Preparation protocols of a β (1-40) promote the formation of polymorphic aggregates and altered interactions with lipid bilayers. <i>Biochemistry</i> , 2014 , 53, 7038-50	3.2	16
643	A hexameric peptide barrel as building block of amyloid- β protofibrils. 2014 , 53, 12756-60		105
642	Imaging of Amyloid- β Aggregation Using a Novel Quantum dot Nanoprobe and its Advanced Applications. 2014 , 121-131		1
641	Capping of a β 2 oligomers by small molecule inhibitors. <i>Biochemistry</i> , 2014 , 53, 7893-903	3.2	57
640	Genome-wide analysis of <i>Saccharomyces cerevisiae</i> identifies cellular processes affecting intracellular aggregation of Alzheimer's amyloid- β 2: importance of lipid homeostasis. 2014 , 25, 2235-49		21
639	Differential regulation of amyloid precursor protein sorting with pathological mutations results in a distinct effect on amyloid- β production. 2014 , 131, 407-12		5
638	O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. 2014 , 426, 1736-52		83
637	Difference in dimer conformation between amyloid- β (142) and (143) proteins: Replica exchange molecular dynamics simulations in water. 2014 , 595-596, 242-249		17
636	Amyloid- β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. 2014 , 35 Suppl 2, S29-34		96

635	Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life. 2014 , 10, e27-39	9
634	Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines. 2014 , 88, 450-67	119
633	Targeted studies on the interaction of nicotine and morin molecules with amyloid β protein. 2014 , 20, 2109	12
632	Dipeptidyl peptidase-4 inhibition by <i>Pterocarpus marsupium</i> and <i>Eugenia jambolana</i> ameliorates streptozotocin induced Alzheimer's disease. 2014 , 267, 55-65	34
631	Improved chemical synthesis of hydrophobic A β peptides using addition of C-terminal lysines later removed by carboxypeptidase B. 2014 , 102, 206-21	16
630	Simulations of monomeric amyloid β peptide (1-40) with varying solution conditions and oxidation state of Met35: implications for aggregation. 2014 , 545, 44-52	28
629	Clioquinol promotes the degradation of metal-dependent amyloid- β oligomers to restore endocytosis and ameliorate A β toxicity. 2014 , 111, 4013-8	124
628	Activity-independent release of the amyloid β peptide from rat brain nerve terminals. 2014 , 566, 125-30	15
627	Amyloid-based nanosensors and nanodevices. 2014 , 43, 5326-45	129
626	A cellular model of amyloid precursor protein processing and amyloid- β peptide production. 2014 , 223, 114-22	15
625	CD47 does not mediate amyloid- β (1-42) protofibril-stimulated microglial cytokine release. 2014 , 454, 239-44	7
624	Fluorinated beta-sheet breaker peptides. 2014 , 2, 2259-2264	36
623	The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid- β aggregation. 2014 , 289, 30977-89	116
622	Specific aromatic foldamers potently inhibit spontaneous and seeded A β 2 and A β 3 fibril assembly. 2014 , 464, 85-98	12
621	Designing BODIPY-based probes for fluorescence imaging of β amyloid plaques. 2014 , 4, 51032-51037	21
620	In vitro amyloidogenic peptides of galectin-7: possible mechanism of amyloidogenesis of primary localized cutaneous amyloidosis. 2014 , 289, 29195-207	6
619	Impact of sequence on the molecular assembly of short amyloid peptides. 2014 , 82, 1469-83	13
618	Molecular tethering effect of C-terminus of amyloid peptide a β 2. 2014 , 8, 9503-10	31

617	Turn plasticity distinguishes different modes of amyloid- β aggregation. 2014 , 136, 4913-9		34
616	Molecular drug targets and therapies for Alzheimer's disease. 2014 , 5,		14
615	The C-terminal threonine of A β 3 nucleates toxic aggregation via structural and dynamical changes in monomers and protofibrils. <i>Biochemistry</i> , 2014 , 53, 3095-105	3.2	30
614	Complex relationships between substrate sequence and sensitivity to alterations in β -secretase processivity induced by β -secretase modulators. <i>Biochemistry</i> , 2014 , 53, 1947-57	3.2	14
613	A commonly used Drosophila model of Alzheimer's disease generates an aberrant species of amyloid- β with an additional N-terminal glutamine residue. 2014 , 588, 3739-43		5
612	A label-free electrical assay of fibrous amyloid β based on semiconductor biosensing. 2014 , 50, 3476-9		14
611	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. 2014 , 2, 83		29
610	Dimerization process of amyloid- β (29-42) studied by the Hamiltonian replica-permutation molecular dynamics simulations. 2014 , 118, 11428-36		29
609	Role for the neurexin-neurologin complex in Alzheimer's disease. 2014 , 35, 746-56		32
608	Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process. 2014 , 40, 1-17		24
607	Inhibitory effect of selenoprotein P on Cu(+)/Cu(2+)-induced A β 2 aggregation and toxicity. 2014 , 53, 1672-8		32
606	Chimera-induced folding: implications for amyloidosis. 2014 , 15, 2992-3001		
605	Photophysical study of Thioflavin T as fluorescence marker of amyloid fibrils. 2014 , 110, 97-105		80
604	Excessive hydrogen peroxide enhances the attachment of amyloid β -42 in the lens epithelium of UPL rats, a hereditary model for cataracts. 2014 , 315, 55-64		19
603	Direct observations of amyloid β self-assembly in live cells provide insights into differences in the kinetics of A β (1-40) and A β (1-42) aggregation. 2014 , 21, 732-42		86
602	Effect of D23N mutation on the dimer conformation of amyloid β proteins: ab initio molecular simulations in water. 2014 , 50, 113-24		6
601	Zinc ion induced prefibrillar oligomerization of A β peptides: From nanocoin to nanobelt. 2014 , 608, 201-206		2
600	The murine version of BAN2401 (mAb158) selectively reduces amyloid- β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. 2015 , 43, 575-88		91

599	A Hexameric Peptide Barrel as Building Block of Amyloid- β Protofibrils. 2014 , 126, 12970-12974	7
598	Effect of high glucose levels on amyloid β production in retinas of spontaneous diabetes mellitus Otsuka Long-Evans Tokushima fatty rats. 2015 , 38, 601-10	7
597	The Extinction Coefficient of N-Methylated A β 40 Depends on the Position of N-Methylation. 2015 , 44, 35-37	1
596	Varied Probability of Staying Collapsed/Extended at the Conformational Equilibrium of Monomeric A β 0 and A β 2. 2015 , 5, 11024	12
595	Nucleation and fibrillation dynamics of A β 1-40 peptides on liquid-solid surface studied by total-internal-reflection fluorescence microscopy coupled with quartz-crystal microbalance biosensor. 2015 , 54, 07HE01	2
594	Modulation of A β 2 in vivo by β -secretase modulator in primates and humans. 2015 , 7, 55	8
593	A β 2 and A β 0: similarities and differences. 2015 , 21, 522-9	71
592	Novel CSF biomarkers for Alzheimer's disease. 2015 , 10, 511-514	3
591	The roles of lipid and glucose metabolism in modulation of β amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. 2015 , 7, 199	107
590	Therapeutic potential of mGluR5 targeting in Alzheimer's disease. 2015 , 9, 215	53
589	Systematic A β Analysis in Drosophila Reveals High Toxicity for the 1-42, 3-42 and 11-42 Peptides, and Emphasizes N- and C-Terminal Residues. 2015 , 10, e0133272	23
588	The role of macropinocytosis in the propagation of protein aggregation associated with neurodegenerative diseases. 2015 , 6, 277	35
587	A novel method for expression and purification of authentic amyloid- β with and without (15)N labels. 2015 , 113, 63-71	10
586	High resolution structural characterization of A β 2 amyloid fibrils by magic angle spinning NMR. 2015 , 137, 7509-18	86
585	Interaction of (B) / (L) -peptides, consisting of Val-Ala-Leu segments, with POPC giant unilamellar vesicles (GUVs) and white blood cancer cells (U937)—a new type of cell-penetrating peptides, and a surprising chain-length dependence of their vesicle- and cell-lysing activity. 2015 , 12, 697-732	13
584	The cell biology of aging. 2015 , 26, 4524-31	88
583	Cerebrospinal Fluid in Clinical Neurology. 2015 ,	13
582	Towards ratiometric sensing of amyloid fibrils in vitro. 2015 , 21, 3425-34	19

581	Small liposomes accelerate the fibrillation of amyloid β (1-40). 2015 , 290, 815-26	58
580	Site-directed mutagenesis reveals regions implicated in the stability and fiber formation of human β light chains. 2015 , 290, 2577-92	9
579	Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer's disease models. 2015 , 304, 316-27	56
578	Amyloid- β s a biomarker for Alzheimer's disease: quantification methods in body fluids. 2015 , 12, 343-54	18
577	Role of Apolipoprotein E in β Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF A β IN VITRO AND BRAIN A β DEPOSITION IN VIVO. 2015 , 290, 15163-74	32
576	Clearance systems in the brain-implications for Alzheimer disease. 2015 , 11, 457-70	759
575	Specific interactions between amyloid- β peptide and curcumin derivatives: Ab initio molecular simulations. 2015 , 633, 139-145	7
574	Dementia of the eye: the role of amyloid beta in retinal degeneration. 2015 , 29, 1013-26	98
573	Mechanical Properties and Failure of Biopolymers: Atomistic Reactions to Macroscale Response. 2015 , 369, 317-43	12
572	GPR84 deficiency reduces microgliosis, but accelerates dendritic degeneration and cognitive decline in a mouse model of Alzheimer's disease. 2015 , 46, 112-20	34
571	Quantitative assessment of A β peptide in brain, cerebrospinal fluid and plasma following oral administration of β -secretase inhibitor MRK-560 in rats. 2015 , 125, 616-24	2
570	The role of APOE-e4 and beta amyloid in the differential rate of recovery from ECT: a review. 2015 , 5, e539	7
569	A β 3 is neurotoxic and primes aggregation of A β 0 in vivo. 2015 , 130, 35-47	31
568	Study on the inter- and intra-peptide salt-bridge mechanism of A β 3-28 oligomer interaction with small molecules: QM/MM method. 2015 , 11, 2031-41	14
567	Baicalin attenuates alzheimer-like pathological changes and memory deficits induced by amyloid β -42 protein. 2015 , 30, 537-44	41
566	Plasma amyloid- β and risk of Alzheimer's disease in the Framingham Heart Study. 2015 , 11, 249-57.e1	66
565	A novel tacrine-dihydropyridine hybrid (-)SCR1693 induces tau dephosphorylation and inhibits A β generation in cells. 2015 , 754, 134-9	11
564	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. 2015 , 193-231	

563	Biophysical comparison of soluble amyloid- β (1-42) protofibrils, oligomers, and protofilaments. <i>Biochemistry</i> , 2015 , 54, 2193-204	3.2	32
562	Self healing hydrogels composed of amyloid nano fibrils for cell culture and stem cell differentiation. 2015 , 54, 97-105		127
561	Amyloid biomarkers in Alzheimer's disease. 2015 , 36, 297-309		320
560	Highly Sensitive FRET-FCS Detects Amyloid β Peptide Oligomers in Solution at Physiological Concentrations. 2015 , 87, 11700-5		32
559	Protein structures in Alzheimer's disease: The basis for rationale therapeutic design. 2015 , 588, 1-14		11
558	Graphene quantum dots for the inhibition of β amyloid aggregation. 2015 , 7, 19060-5		90
557	The A β 0 and A β 2 peptides self-assemble into separate homomolecular fibrils in binary mixtures but cross-react during primary nucleation. 2015 , 6, 4215-4233		91
556	Polymer Mechanochemistry. 2015 ,		20
555	Antibody against Small Aggregated Peptide Specifically Recognizes Toxic A β 42 Oligomers in Alzheimer's Disease. 2015 , 6, 1981-9		14
554	Structural differences of amyloid- β fibrils revealed by antibodies from phage display. 2015 , 15, 57		8
553	Quantitative analysis of the capillary network of aged APPswe/PS1dE9 transgenic mice. 2015 , 36, 2954-2962		5
552	The keystone of Alzheimer pathogenesis might be sought in A β physiology. 2015 , 307, 26-36		80
551	Quantitative detection of amyloid- β peptides by mass spectrometry: state of the art and clinical applications. 2015 , 53, 1483-93		21
550	Intraneuronal A β accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3. 2015 , 36, 886-900		53
549	A β self-association and adsorption on a hydrophobic nanosurface: competitive effects and the detection of small oligomers via electrical response. 2015 , 11, 269-79		13
548	Seizures in Alzheimer's disease. 2015 , 286, 251-63		85
547	A β influences Cytoskeletal Signaling Cascades with Consequences to Alzheimer's Disease. 2015 , 52, 1391-1407		25
546	Astrocytes and microglia but not neurons preferentially generate N-terminally truncated A β peptides. 2015 , 73, 24-35		36

545 Alternative Splicing and Alzheimer's Disease. **2016,**

544 . **2016,** 4

543 Roles of Sodium-Calcium Exchanger Isoform-3 toward Calcium Ion Regulation in Alzheimer's Disease. **2016,** 06, 2

542 Hyperglycemia Enhances the Production of Amyloid β -42 in the Lenses of Otsuka Long-Evans Tokushima Fatty Rats, a Model of Human Type 2 Diabetes. **2016,** 57, 1408-17 16

541 Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting A β Using Several Synthetic and Herbal Compounds. **2016,** 2016, 7361613 82

540 Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnesic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. **2016,** 8, 30 10

539 Early Dementia Screening. **2016,** 6, 41

538 Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer's Disease Phenotypes. **2016,** 11, e0161969 277

537 Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. **2016,** 17, 827-845 38

536 Dysregulation of intracellular trafficking and endosomal sorting in Alzheimer's disease: controversies and unanswered questions. **2016,** 473, 1977-93 43

535 The amyloid cascade hypothesis: are we poised for success or failure?. **2016,** 139 Suppl 2, 237-252 235

534 Membrane trafficking and proteolytic activity of β -secretase in Alzheimer's disease. **2016,** 397, 827-35 3

533 Design, synthesis, and evaluation of Trolox-conjugated amyloid- β -terminal peptides for therapeutic intervention in an in vitro model of Alzheimer's disease. **2016,** 24, 4138-4143 10

532 Differential Membrane Toxicity of Amyloid- β -Fragments by Pore Forming Mechanisms. **2016,** 51, 689-99 29

531 Anti-Viral Properties of Amyloid- β -Peptides. **2016,** 54, 859-878 53

530 A β immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. **2016,** 18, e13 26

529 Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms. **2016,** 6, 28658 38

528 Targets and Strategies Toward the Development of Alzheimer Therapeutics. **2016,** 1-25

527	Ab initio molecular simulations on specific interactions between amyloid- β peptide and new curcumin derivatives. 2016,	1
526	Ab initio fragment molecular orbital calculations on the specific interactions between amyloid- β peptides in an in vivo amyloid- β fibril. 2016,	1
525	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease. 2016, 51, 1085-97	10
524	A β 0 has a subtle effect on A β 2 protofibril formation, but to a lesser degree than A β 2 concentration, in A β 2/A β 0 mixtures. 2016, 597, 1-11	11
523	The inhibitory mechanism of a fullerene derivative against amyloid- β peptide aggregation: an atomistic simulation study. 2016, 18, 12582-91	53
522	Deposition of C-terminally truncated A β species A β 7 and A β 9 in Alzheimer's disease and transgenic mouse models. 2016, 4, 24	22
521	Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins. 2016, 1862, 105-12	8
520	Effect of Ca(2+) on A β 0 fibrillation is characteristically different. 2016, 89, 297-304	1
519	Nucleoside-2',3'/3',5'-bis(thio)phosphate antioxidants are also capable of disassembly of amyloid beta42-Zn(ii)/Cu(ii) aggregates via Zn(ii)/Cu(ii)-chelation. 2016, 14, 4640-53	7
518	Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. 2016, 145, 8-13	113
517	Genomics of Alzheimer Disease: A Review. 2016, 73, 867-74	83
516	Amyloid- β (1-42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity. 2016, 291, 19590-606	61
515	Molecular Dynamics Simulations of Amyloid β Peptide (1-42): Tetramer Formation and Membrane Interactions. 2016, 111, 937-49	59
514	β Amyloid increases neurocan expression through regulating Sox9 in astrocytes: A potential relationship between Sox9 and chondroitin sulfate proteoglycans in Alzheimer's disease. 2016, 1646, 377-383	14
513	Potential mechanisms and implications for the formation of tau oligomeric strains. 2016, 51, 482-496	40
512	Probing the role of metal cations on the aggregation behavior of amyloid β peptide at a single molecule level by AFM. 2016, 18, 1	1
511	APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease. 2016, 36, 8471-86	36
510	Implications for Alzheimer's disease of an atomic resolution structure of amyloid- β (1-42) fibrils. 2016, 113, 9398-400	24

509	Atomic-resolution structure of a disease-relevant A β (1-42) amyloid fibril. 2016 , 113, E4976-84	557
508	Amyloid- β 2 protofibrils are internalized by microglia more extensively than monomers. 2016 , 1648, 485-495	21
507	Self-Assembly of Biohybrid Polymers. 2016 , 193-229	2
506	Transmembrane Substrate Determinants for γ -Secretase Processing of APP CTF <i>Biochemistry</i> , 2016 , 55, 5675-5688	3.2 28
505	Inhibition of Amyloid β Protein Fibrillation via Carboxypeptidase Y after Protein Trapping Using Immunoaffinity Membranes. 2016 , 45, 1241-1243	3
504	Structural Polymorphism of Alzheimer's β Amyloid Fibrils as Controlled by an E22 Switch: A Solid-State NMR Study. 2016 , 138, 9840-52	61
503	Specific combinations of presenilins and Aph1s affect the substrate specificity and activity of γ -secretase. 2016 , 478, 1751-7	11
502	Amyloid beta peptides inside a reconstituted cell-like liposomal system: aggregation, FRET, fluorescence oscillations and solvation dynamics. 2016 , 18, 30444-30451	15
501	De novo design of a biologically active amyloid. 2016 , 354,	44
500	Rapid β oligomer formation mediated by the A β terminus initiates an amyloid assembly pathway. 2016 , 7, 12419	44
499	Hydrogen Exchange Mass Spectrometry for the Analysis of Ligand Binding and Protein Aggregation. 2016 , 185-207	3
498	The ability of apolipoprotein E fragments to promote intraneuronal accumulation of amyloid beta peptide 42 is both isoform and size-specific. 2016 , 6, 30654	27
497	Citrullination and deamidation affect aggregation properties of amyloid β proteins. 2016 , 23, 234-241	14
496	Therapeutic Targeting of A β 2. 2016 , 77-96	
495	Oligomer Formation of Amyloid- β (29-42) from Its Monomers Using the Hamiltonian Replica-Permutation Molecular Dynamics Simulation. 2016 , 120, 6555-61	21
494	Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?. 2016 , 31, 668-75	23
493	Fluorimetric detection of the earliest events in amyloid β oligomerization and its inhibition by pharmacologically active liposomes. 2016 , 1860, 746-56	8
492	Nuclear magnetic resonance evidence for the dimer formation of beta amyloid peptide 1-42 in 1,1,1,3,3,3-hexafluoro-2-propanol. 2016 , 498, 59-67	12

491	Intracerebral Hemorrhage. 2016 , 466-515.e12		2
490	Validation and Characterization of a Novel Peptide That Binds Monomeric and Aggregated β Amyloid and Inhibits the Formation of Neurotoxic Oligomers. 2016 , 291, 547-59		11
489	Non-Amyloid- β Component of Human β Synuclein Oligomers Induces Formation of New A β Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases. 2016 , 7, 46-55		36
488	Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. 2016 , 73, 13-31		67
487	Detection of amyloid- β Fibrils using the DNA-intercalating dye YOYO-1: Binding mode and fibril formation kinetics. 2016 , 469, 313-8		7
486	Monomeric A β (1-40) and A β (1-42) Peptides in Solution Adopt Very Similar Ramachandran Map Distributions That Closely Resemble Random Coil. <i>Biochemistry</i> , 2016 , 55, 762-75	3.2	121
485	C-Terminal Fragment, A β 2-37, Analogues Protect Against A β Aggregation-Induced Toxicity. 2016 , 7, 615-23		26
484	Systems Pharmacology Analysis of the Amyloid Cascade after β Secretase Inhibition Enables the Identification of an A β 2 Oligomer Pool. 2016 , 357, 205-16		9
483	Opposing Effects of Cucurbit[7]uril and 1,2,3,4,6-Penta-O-galloyl- β -D-glucopyranose on Amyloid β 5-35 Assembly. 2016 , 7, 218-26		20
482	Dynamic Protein Interaction Networks and New Structural Paradigms in Signaling. 2016 , 116, 6424-62		118
481	Sulindac Sulfide Induces the Formation of Large Oligomeric Aggregates of the Alzheimer's Disease Amyloid- β Peptide Which Exhibit Reduced Neurotoxicity. <i>Biochemistry</i> , 2016 , 55, 1839-49	3.2	37
480	Stabilization of native amyloid β protein oligomers by Copper and Hydrogen peroxide Induced Cross-linking of Unmodified Proteins (CHICUP). 2016 , 1864, 249-259		28
479	The influence of the localised charge of C- and N-termini on peptide self-assembly. 2016 , 12, 373-7		5
478	Propagation of A β pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. 2016 , 131, 5-25		54
477	Advanced Assay Monitoring APP-Carboxyl-Terminal Fragments as Markers of APP Processing in Alzheimer Disease Mouse Models. 2016 , 1303, 117-23		5
476	Potential of tocotrienols in the prevention and therapy of Alzheimer's disease. 2016 , 31, 1-9		23
475	C-Terminal Threonine Reduces A β 3 Amyloidogenicity Compared with A β 2. 2016 , 428, 274-291		15
474	Common Impact of Chronic Kidney Disease and Brain Microhemorrhages on Cerebral A β Pathology in SHRSP. 2017 , 27, 169-180		9

473	Selecting A β isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. 2017 , 11, 169-178	10
472	Specific interactions between amyloid- β peptides in an amyloid- β hexamer with three-fold symmetry: Ab initio fragment molecular orbital calculations in water. 2017 , 672, 13-20	5
471	Comparison of neurotoxicity of different aggregated forms of A β 0, A β 2 and A β 3 in cell cultures. 2017 , 23, 245-251	18
470	The role of histidines in amyloid β fibril assembly. 2017 , 591, 1167-1175	22
469	Platelets and Neurodegenerative Diseases. 2017 , 1209-1224	1
468	A positive feedback loop between nitric oxide and amyloid β (1-42) accelerates mitochondrial damage in human lens epithelial cells. 2017 , 381, 19-30	13
467	Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases. 2017 , 177, 32-43	30
466	Cerebrosides from Sea Cucumber Protect Against Oxidative Stress in SAMP8 Mice and PC12 Cells. 2017 , 20, 392-402	18
465	N-Terminus Binding Preference for Either Tanshinone or Analogue in Both Inhibition of Amyloid Aggregation and Disaggregation of Preformed Amyloid Fibrils-Toward Introducing a Kind of Novel Anti-Alzheimer Compounds. 2017 , 8, 1577-1588	16
464	An improvement on the prediction power of the 3D-QSAR CoMFA models using a hybrid of statistical and machine learning methods: a case study on β -secretase modulators of Alzheimer's disease. 2017 , 26, 1184-1200	3
463	Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade. 2017 , 86, 27-68	1248
462	Alzheimer's Disease II. 2017 ,	2
461	Effects of phenothiazine-structured compounds on APP processing in Alzheimer's disease cellular model. 2017 , 138, 82-89	11
460	Endocytic uptake of monomeric amyloid- β peptides is clathrin- and dynamin-independent and results in selective accumulation of A β (1-42) compared to A β (1-40). 2017 , 7, 2021	51
459	Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. 2017 , 58, 2083-2101	50
458	Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate. 2017 , 58, 821-828	8
457	Dihydropyrimidine-Thiones and Clioquinol Synergize To Target β -Amyloid Cellular Pathologies through a Metal-Dependent Mechanism. 2017 , 8, 2039-2055	12
456	β -Secretase Modulators as A β 2-Lowering Pharmacological Agents to Treat Alzheimer's Disease. 2017 , 87-118	6

455	Optimization of d-Peptides for A β Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic A β Oligomers. 2017 , 8, 1889-1900	14
454	A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer's Disease in 5XFAD Mice. 2017 , 58, 389-400	4
453	Seed-Induced Heterogeneous Cross-Seeding Self-Assembly of Human and Rat Islet Polypeptides. 2017 , 2, 784-792	18
452	Mouse Models of Alzheimer's Disease. 2017 , 57, 1171-1183	135
451	Clinical validity of cerebrospinal fluid A β 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. 2017 , 52, 196-213	73
450	Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A β 2 and A β 0 peptides by γ -secretase. 2017 , 114, E476-E485	173
449	Cross-seeding between A β 0 and A β 2 in Alzheimer's disease. 2017 , 591, 177-185	30
448	Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?. 2017 , 140, 703-717	79
447	Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid- β Aggregation: Potential Therapeutics of Alzheimer's Disease. 2017 , 19, 55-80	129
446	Effects of altered RTN3 expression on BACE1 activity and Alzheimer's neuritic plaques. 2017 , 28, 145-154	12
445	A computational study of self-assembled hexapeptide inhibitors against amyloid- β aggregation. 2016 , 19, 155-166	12
444	Computational Models of Pharmacological and Immunological Treatment in Alzheimer's Disease. 2017 , 99-108	1
443	The role of the immune system in Alzheimer disease: Etiology and treatment. 2017 , 40, 84-94	86
442	Amyloid β peptides 1-40 and 1-42 form oligomers with mixed β sheets. 2017 , 8, 8247-8254	22
441	Proposal for novel curcumin derivatives as potent inhibitors against Alzheimer's disease: Ab initio molecular simulations on the specific interactions between amyloid-beta peptide and curcumin. 2017 , 685, 482-489	2
440	Graphene oxide-iron oxide nanocomposite as an inhibitor of A β 2 amyloid peptide aggregation. 2017 , 159, 540-545	12
439	Pseudo-peptide amyloid- β blocking inhibitors: molecular dynamics and single molecule force spectroscopy study. 2017 , 1865, 1707-1718	10
438	2-Arachidonoylglycerol metabolism is differently modulated by oligomeric and fibrillar conformations of amyloid beta in synaptic terminals. 2017 , 362, 168-180	5

- 437 MMP-7 cleaves amyloid β fragment peptides and copper ion inhibits the degradation. **2017**, 30, 797-807 8
- 436 Amyloid precursor protein drives down-regulation of mitochondrial oxidative phosphorylation independent of amyloid beta. **2017**, 7, 9835 18
- 435 Fully Atomistic A β 0 and A β 2 Oligomers in Water: Observation of Porelike Conformations. **2017**, 13, 4567-4583 19
- 434 Structural studies of amyloid- β peptides: Unlocking the mechanism of aggregation and the associated toxicity. **2017**, 140, 176-192 42
- 433 Cryo-EM structures of human β -secretase. **2017**, 46, 55-64 16
- 432 CART modulates beta-amyloid metabolism-associated enzymes and attenuates memory deficits in APP/PS1 mice. **2017**, 39, 885-894 17
- 431 Femtosecond-Laser-Enhanced Amyloid Fibril Formation of Insulin. **2017**, 33, 8311-8318 9
- 430 Aggregation and Fibril Structure of A β and A β *Biochemistry*, **2017**, 56, 4850-4859 3,2 16
- 429 Using an NMR metabolomics approach to investigate the pathogenicity of amyloid-beta and alpha-synuclein. **2017**, 13, 151 10
- 428 Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways. **2017**, 114, E6962-E6971 66
- 427 Role of Vitamin D in Amyloid clearance via LRP-1 upregulation in Alzheimer's disease: A potential therapeutic target?. **2017**, 85, 36-42 25
- 426 Biomarkers for the Early Detection and Progression of Alzheimer's Disease. **2017**, 14, 35-53 78
- 425 Aging, microglia and cytoskeletal regulation are key factors in the pathological evolution of the APP23 mouse model for Alzheimer's disease. **2017**, 1863, 395-405 9
- 424 Topics in Biomedical Gerontology. **2017**, 34, 1-16 34
- 423 Integrated late onset Alzheimer's disease (LOAD) susceptibility genes: Cholesterol metabolism and trafficking perspectives. **2017**, 597, 10-16 34
- 422 Changes in Social Behavior Associated with Alzheimer's Disease-Related A β Pathology. **2017**, 253-265 20
- 421 Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice. **2017**, 95, 992-999 5
- 420 Prion-like disorders and Transmissible Spongiform Encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins. **2017**, 483, 1125-1136 20

419	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. 2018 , 61, 793-801	7
418	Perplexity of Amyloid β Protein Oligomer Formation: Relevance to Alzheimer's Disease. 2017 , 1-50	3
417	Structural Discrimination between A β (1-40) and A β (1-42) Peptides in Films with Vibrational Circular Dichroism Spectroscopy. 2017 , 33, 79-82	3
416	Molecular dynamics and ab initio molecular orbital calculations on conformational change of amyloid- β monomers in an in vivo amyloid- β monomer. 2017 ,	
415	10. Genetics of Alzheimer's disease. 2017 , 117-132	
414	Nature Versus Nurture: Does Proteostasis Imbalance Underlie the Genetic, Environmental, and Age-Related Risk Factors for Alzheimer's Disease?. 2017 , 5,	2
413	Cerebrospinal Fluid A β 3 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to A β 2. 2017 , 9, 210	17
412	APP Function and Lipids: A Bidirectional Link. 2017 , 10, 63	54
411	Interplay of Energetics and ER Stress Exacerbates Alzheimer's Amyloid- β Toxicity in Yeast. 2017 , 10, 232	18
410	Amyloid β -43 Accumulates in the Lens Epithelium of Cortical Opacification in Japanese Patients. 2017 , 58, 3294-3302	4
409	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease. 2017 , 65-135	1
408	Role of Curcumin in Treatment of Alzheimer Disease. 2017 , 04,	10
407	Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease. 2017 , 40, 613-620	88
406	The past, present, and future of disease-modifying therapies for Alzheimer's disease. 2017 , 93, 757-771	24
405	Probing the Structure and Function Relationships of Presenilin by Substituted-Cysteine Accessibility Method. 2017 , 584, 185-205	10
404	QSAR classification and regression models for β secretase inhibitors using relative distance matrices. 2018 , 29, 355-383	3
403	Nanogels of dual inhibitor-modified hyaluronic acid function as a potent inhibitor of amyloid β protein aggregation and cytotoxicity. 2018 , 8, 3505	22
402	Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid- β 2018 , 8, 6412	83

401	Positive effect of strong acidity on the twist of A β fibrils and the counteraction of A β N-terminus. 2018 , 82, 59-66	1
400	Determining the Potential of Mean Force for Amyloid- β Dimerization: Combining Self-Consistent Field Theory with Molecular Dynamics Simulation. 2018 , 14, 2696-2704	11
399	High pressure NMR reveals conformational perturbations by disease-causing mutations in amyloid Epeptide. 2018 , 54, 4609-4612	6
398	Secretase inhibitors for the treatment of Alzheimer's disease: Long road ahead. 2018 , 148, 436-452	88
397	Alterations in spontaneous delta and gamma activity might provide clues to detect changes induced by amyloid- β administration. 2018 , 47, 1013-1023	6
396	Assembly of Nanoconjugates as New Kind Inhibitor of the Aggregation of Amyloid Peptides Associated with Alzheimer's Disease. 2018 , 35, 1700384	5
395	Critical aggregation concentration for the formation of early Amyloid- β (1-42) oligomers. 2018 , 8, 1783	80
394	Towards an experimental classification system for membrane active peptides. 2018 , 8, 1194	9
393	Mammalian amyloidogenic proteins promote prion nucleation in yeast. 2018 , 293, 3436-3450	10
392	Amyloid Beta Peptide VHHQ, KLVFF, and IIGLMVGGVV Domains Involved in Fibrilization: AFM and Electrochemical Characterization. 2018 , 90, 2285-2292	24
391	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. 2018 , 19, 59-67	5
390	Highly water pressurized brown rice improves cognitive dysfunction in senescence-accelerated mouse prone 8 and reduces amyloid beta in the brain. 2018 , 18, 110	9
389	Viscoelasticity Response during Fibrillation of Amyloid β Peptides on a Quartz-Crystal-Microbalance Biosensor. 2018 , 34, 5474-5479	6
388	New Insights Into Autophagy Dysfunction Related to Amyloid Beta Toxicity and Neuropathology in Alzheimer's Disease. 2018 , 336, 321-361	22
387	A β 2 Protofibrils Interact with and Are Trafficked through Microglial-Derived Microvesicles. 2018 , 9, 1416-1425	16
386	Time- and dose-related effects of amyloid beta1-40 on retina and optic nerve morphology in rats. 2018 , 128, 952-965	8
385	Binding Patterns Associated A β HSP60 p458 Conjugate to HLA-DR-DRB Allele of Human in Alzheimer's Disease: An In Silico Approach. 2018 , 10, 93-104	3
384	Diagnosis and management of neuropathies associated with plasma cell dyscrasias. 2018 , 36, 3-14	11

383	In silico investigation on the inhibition of A β aggregation by A β peptide by potential of mean force study. 2018 , 36, 741-752	6
382	Spectroscopic Signature for Stable A β Amyloid Fibrils versus A β Sheet-Rich Oligomers. 2018 , 122, 144-153	37
381	Discovery of novel scaffolds for A β -secretase modulators without an arylimidazole moiety. 2018 , 26, 435-442	13
380	The Emerging Relationship Between Interstitial Fluid-Cerebrospinal Fluid Exchange, Amyloid- β and Sleep. 2018 , 83, 328-336	80
379	Alzheimer's disease as oligomeropathy. 2018 , 119, 57-70	67
378	Periodontal disease exacerbates Alzheimer's disease. 2018 , 60, 147-152	
377	miRNAs as biofluid markers for diagnostics of Alzheimer's disease: recent status and perspectives. 2018 , 37, 495-514	1
376	3 .Neuropathologie und molekulare Mechanismen. 2018 , 35-122	0
375	Probing the mechanism of inhibition of amyloid- β (1-42)-induced neurotoxicity by the chaperonin GroEL. 2018 , 115, E11924-E11932	19
374	Role of purinergic receptors in the Alzheimer's disease. 2018 , 14, 331-344	41
373	Anti- α IIb Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer's Disease. 2018 , 15, 1123-1135	8
372	On the Applicability of Force Fields To Study the Aggregation of Amyloidogenic Peptides Using Molecular Dynamics Simulations. 2018 , 14, 6063-6075	51
371	Cell surface proteoglycan-mediated uptake and accumulation of the Alzheimer's disease peptide A β (1-42). 2018 , 1860, 2204-2214	12
370	Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition. 2018 , 11, 302	18
369	An Efficient Method for the Expression and Purification of A β (M1-42). <i>Biochemistry</i> , 2018 , 57, 3861-3866	3.2 10
368	A β Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling. 2017 , 8, 969	10
367	The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials. 2018 , 9,	58
366	Insights into the Origin of Distinct Medin Fibril Morphologies Induced by Incubation Conditions and Seeding. 2018 , 19,	3

365	The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease. 2018 , 6, 62	3
364	Fe(II) formation after interaction of the amyloid β peptide with iron-storage protein ferritin. 2018 , 44, 237-243	8
363	Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review). 2018 , 18, 639-655	10
362	Kinetics and mechanical stability of the fibril state control fibril formation time of polypeptide chains: A computational study. 2018 , 148, 215106	16
361	Self-Assembled Curcumin-Poly(carboxybetaine methacrylate) Conjugates: Potent Nano-Inhibitors against Amyloid β Protein Fibrillogenesis and Cytotoxicity. 2019 , 35, 1846-1857	26
360	Plasma amyloid and tau as dementia biomarkers in Down syndrome: Systematic review and meta-analyses. 2019 , 79, 684-698	14
359	Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease. 2019 , 168, 99-145	17
358	Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid β fibrils. 2019 , 14, e0219465	7
357	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A β and Tau Species. 2019 , 13, 659	122
356	Alzheimer's Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts. 2019 , 13, 309	61
355	Structure and Physicochemical Properties of the A β 2 Tetramer: Multiscale Molecular Dynamics Simulations. 2019 , 123, 7253-7269	18
354	A simplified and sensitive immunoprecipitation mass spectrometry protocol for the analysis of amyloid-beta peptides in brain tissue.. 2019 , 14 Pt B, 83-88	1
353	Effects of Cu(II) on the aggregation of amyloid- β 2019 , 24, 1197-1215	14
352	Identifying Terminal Assembly Propensity of Amyloid Peptides by Scanning Tunneling Microscopy. 2019 , 20, 103-107	3
351	Oligomers imaging of amyloid- β 42 by scanning tunneling microscopy. 2019 , 58, SIIB30	2
350	A β Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology. 2019 , 12, 233	16
349	Amyloid Precursor Protein Mediates Neuronal Protection from Rotenone Toxicity. 2019 , 56, 5471-5482	8
348	Size-effect of gold nanorods on modulating the kinetic process of amyloid- β aggregation. 2019 , 734, 136702	2

347	A β 3 in human Alzheimer's disease: effects of active A β 2 immunization. 2019 , 7, 141	13
346	Inflammatory mechanisms in neurodegeneration. 2019 , 149, 562-581	49
345	Novel compound VB-037 inhibits A β aggregation and promotes neurite outgrowth through enhancement of HSP27 and reduction of P38 and JNK-mediated inflammation in cell models for Alzheimer's disease. 2019 , 125, 175-186	10
344	Four new cembranoids from the Chinese soft coral <i>Sinularia</i> sp. and their anti-A β aggregation activities. 2019 , 136, 104176	10
343	Amyloid- β Peptide-Lipid Bilayer Interaction Investigated by Supercritical Angle Fluorescence. 2019 , 10, 4776-4786	1
342	Intertwined Pathologies of Amyloid- β and Metal Ions in Alzheimer's Disease: Metal-Amyloid- β 2019 , 48, 951-960	12
341	Binary Structure of Amyloid Beta Oligomers Revealed by Dual Recognition Mapping. 2019 , 91, 8422-8428	8
340	Rapid, Refined, and Robust Method for Expression, Purification, and Characterization of Recombinant Human Amyloid beta 1-42. 2019 , 2,	3
339	Effects of in vivo conditions on amyloid aggregation. 2019 , 48, 3946-3996	86
338	Protein Misfolding and ER Stress in Huntington's Disease. 2019 , 6, 20	39
337	Multi-target-directed triazole derivatives as promising agents for the treatment of Alzheimer's disease. 2019 , 87, 572-584	27
336	Chronic cerebral hypoperfusion shifts the equilibrium of amyloid β oligomers to aggregation-prone species with higher molecular weight. 2019 , 9, 2827	21
335	The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. 2019 , 151, 21-32	4
334	Astrocytes infected with <i>Chlamydia pneumoniae</i> demonstrate altered expression and activity of secretases involved in the generation of β amyloid found in Alzheimer disease. 2019 , 20, 6	14
333	Characterizing the structural and thermodynamic properties of A β 2 and A β 0. 2019 , 510, 442-448	11
332	Tautomerization Effect of Histidines on Oligomer Aggregation of β Amyloid(1-40/42) during the Early Stage: Tautomerism Hypothesis for Misfolding Protein Aggregation. 2019 , 10, 2602-2608	16
331	A DFT-Assisted Topological Analysis of Four Polymorphic, S-Shaped A β 2 Fibril Structures. 2019 , 20, 1722-1724	4
330	β Secretase and its modulators: Twenty years and beyond. 2019 , 701, 162-169	26

329	Elucidating the Molecular Determinants of A β Aggregation with Deep Mutational Scanning. 2019 , 9, 3683-3689	13
328	Mitigating Alzheimer's Disease with Natural Polyphenols: A Review. 2019 , 16, 529-543	27
327	Synaptic Elimination in Neurological Disorders. 2019 , 17, 1071-1095	25
326	In search of pathogenic amyloid β peptide in familial Alzheimer's disease. 2019 , 168, 71-78	4
325	Screening a specific Zn(ii)-binding peptide for improving the cognitive decline of Alzheimer's disease in APP/PS1 transgenic mice by inhibiting Zn-mediated amyloid protein aggregation and neurotoxicity. 2019 , 7, 5197-5210	10
324	Potential microRNA-related targets in clearance pathways of amyloid- β novel therapeutic approach for the treatment of Alzheimer's disease. 2019 , 9, 91	19
323	Emerging roles of N- and C-terminally truncated A β species in Alzheimer's disease. 2019 , 23, 991-1004	24
322	Combining molecular dynamics simulations and experimental analyses in protein misfolding. 2019 , 118, 33-110	6
321	Redox proteomics and amyloid β peptide: insights into Alzheimer disease. 2019 , 151, 459-487	44
320	Cu and Zn interactions with A β peptides: consequence of coordination on aggregation and formation of neurotoxic soluble A β oligomers. 2019 , 11, 64-84	48
319	Bax inhibitor 1 is a β -secretase-independent presenilin-binding protein. 2019 , 116, 141-147	8
318	Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease. 2019 , 176, 3464-3474	15
317	How Fluorescent Tags Modify Oligomer Size Distributions of the Alzheimer Peptide. 2019 , 116, 227-238	10
316	Nitration of amyloid- β peptide (1-42) as a protective mechanism for the amyloid- β peptide (1-42) against copper ion toxicity. 2019 , 190, 15-23	10
315	Amyloidogenicity and Cytotoxicity of a Recombinant C-Terminal His-Tagged A β 2019 , 10, 1251-1262	10
314	Beneficial effect of ovocystatin on the cognitive decline in APP/PS1 transgenic mice. 2019 , 64, 65-71	2
313	Alzheimer's Disease and Dementia. 2019 , 25-82	0
312	Functions and dysfunctions of nitric oxide in brain. 2019 , 1865, 1949-1967	80

311	A-type EGCG dimer, a new proanthocyanidins dimer from persimmon fruits, interacts with the amino acid residues of A β 0 which possessed high aggregation-propensity and strongly inhibits its amyloid fibrils formation. 2019 , 52, 492-504	3
310	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. 2019 , 151, 417-434	10
309	Dysfunctional β -Secretase in Familial Alzheimer's Disease. 2019 , 44, 5-11	17
308	Rationale for the development of an Alzheimer's disease vaccine. 2020 , 16, 645-653	5
307	Discovery of N-ethylpyridine-2-carboxamide derivatives as a novel scaffold for orally active β -secretase modulators. 2020 , 28, 115132	6
306	A novel near-infrared fluorescent probe for detection of early-stage A β protofibrils in Alzheimer's disease. 2020 , 56, 1625-1628	15
305	Interactions of a multifunctional di-triazole derivative with Alzheimer's A β monomer and A β protofibril: a systematic molecular dynamics study. 2020 , 22, 1543-1556	19
304	Stabilization Mechanism for a Nonfibrillar Amyloid β Oligomer Based on Formation of a Hydrophobic Core Determined by Dissipative Particle Dynamics. 2020 , 11, 385-394	7
303	β Amyloid Peptide: the Cell Compartment Multi-faceted Interaction in Alzheimer's Disease. 2020 , 37, 250-263	21
302	Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. 2020 , 16, 30-42	171
301	Self-Assembly and Neurotoxicity of β Amyloid (21-40) Peptide Fragment: The Regulatory Role of GxxxG Motifs. 2020 , 15, 293-301	12
300	Neuroprotective effects of brain-derived neurotrophic factor against amyloid beta 1-40-induced retinal and optic nerve damage. 2020 , 51, 2394-2411	9
299	Amyloid Beta-Peptide Increases BACE1 Translation through the Phosphorylation of the Eukaryotic Initiation Factor-2. 2020 , 2020, 2739459	3
298	Alzheimer's Disease: Causes, Mechanisms, and Steps Toward Prevention. 2020 ,	
297	Sequence and structure-based peptides as potent amyloid inhibitors: A review. 2020 , 695, 108614	10
296	TMEM59 Haploinsufficiency Ameliorates the Pathology and Cognitive Impairment in the 5xFAD Mouse Model of Alzheimer's Disease. 2020 , 8, 596030	3
295	Amyloid formation of fish β parvalbumin involves primary nucleation triggered by disulfide-bridged protein dimers. 2020 , 117, 27997-28004	4
294	The inhibition of cellular toxicity of amyloid- β by dissociated transthyretin. 2020 , 295, 14015-14024	7

293	Design and synthesis of β -strand-fixed peptides inhibiting aggregation of amyloid β protein. 2020 , 28, 115676	6
292	Intracisternal injection of beta-amyloid seeds promotes cerebral amyloid angiopathy. 2020 , 89, 628-640	3
291	Models to Study the Propagation of Prions and Prion-Like Proteins. 2020 , 10,	4
290	The coarse-grained plaque: a divergent $A\beta$ plaque-type in early-onset Alzheimer's disease. 2020 , 140, 811-830	20
289	Gliosis Precedes Amyloid- β Deposition and Pathological Tau Accumulation in the Neuronal Cell Cycle Re-Entry Mouse Model of Alzheimer's Disease. 2020 , 4, 243-253	5
288	How Microglia Manages Non-cell Autonomous Vicious Cycling of $A\beta$ Toxicity in the Pathogenesis of AD. 2020 , 13, 593724	3
287	Does Diet Have a Role in the Treatment of Alzheimer's Disease?. 2020 , 12, 617071	5
286	Effect of DNA Origami Nanostructures on hIAPP Aggregation. 2020 , 10,	2
285	Mechanisms of neurodegeneration - Insights from familial Alzheimer's disease. 2020 , 105, 75-85	15
284	Zinc binding promotes greater hydrophobicity in Alzheimer's $A\beta$ 2 peptide than copper binding: Molecular dynamics and solvation thermodynamics studies. 2020 , 88, 1285-1302	6
283	Combating Proteins with Proteins: Engineering Cell-Penetrating Peptide Antagonists of Amyloid- β Aggregation and Associated Neurotoxicity. 2020 , 39, 920-925	3
282	Redox-Dependent Copper Ion Modulation of Amyloid- β (1-42) Aggregation In Vitro. 2020 , 10,	0
281	Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers. 2020 , 161, 59-71	11
280	Optical coherence tomography reveals light-dependent retinal responses in Alzheimer's disease. 2020 , 219, 117022	8
279	Structure Analysis of Amyloid Aggregates at Lipid Bilayers by Supercritical Angle Raman Microscopy. 2020 , 92, 4963-4970	1
278	Expression and purification of amyloid β protein, tau, and β synuclein in : a review. 2020 , 40, 475-489	5
277	Acetylation of $A\beta$ 2 at Lysine 16 Disrupts Amyloid Formation. 2020 , 11, 1178-1191	8
276	Occurrence of Biased Conformations as Precursors of Assembly States in Fibril Elongation of Amyloid- β Fibril Variants: An Study. 2020 , 124, 2798-2805	4

275	Intra-gastrointestinal amyloid- β -42 oligomers perturb enteric function and induce Alzheimer's disease pathology. 2020 , 598, 4209-4223	29
274	Designed Cell-Penetrating Peptide Inhibitors of Amyloid-beta Aggregation and Cytotoxicity. 2020 , 1, 100014	16
273	The effect of sodium dodecyl sulfate concentration on the aggregation behavior of A β (1-42) peptide: Molecular dynamics simulation approach. 2020 , 303, 112651	0
272	Presenilin-1 mutation is associated with a hippocampus defect in alzheimer's disease: Meta-Analysis for neuroimaging research. 2020 , 191, 105679	1
271	Reduced Influence of apoE on A β 3 Aggregation and Reduced Vascular A β 3 Toxicity as Compared with A β 0 and A β 2. 2020 , 57, 2131-2141	3
270	Misfolded amyloid- β 2 impairs the endosomal-lysosomal pathway. 2020 , 77, 5031-5043	14
269	Plasma Amyloid Concentration in Alzheimer's Disease: Performance of a High-Throughput Amyloid Assay in Distinguishing Alzheimer's Disease Cases from Controls. 2020 , 74, 1285-1294	10
268	PHP exposure in rodents produces neuropathology potentially relevant to Alzheimer's disease. 2020 , 437, 152436	2
267	Enhancement of Amyloid β Production in the Lens Epithelium of Japanese Type 2 Diabetic Patients. 2020 , 8,	
266	Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins Relevance to the Symptomatic Treatment of Alzheimer's Disease. 2020 , 12,	18
265	Optimization and biological evaluation of imidazopyridine derivatives as a novel scaffold for β -secretase modulators with oral efficacy against cognitive deficits in Alzheimer's disease model mice. 2020 , 28, 115455	6
264	Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy. 2020 , 2020, 5380346	33
263	Enhanced neprilysin-mediated degradation of hippocampal A β 2 with a somatostatin peptide that enters the brain. 2021 , 11, 789-804	8
262	Danshen (Salvia miltiorrhiza) water extract shows potential neuroprotective effects in Caenorhabditis elegans. 2021 , 266, 113418	6
261	Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice. 2021 , 39, 266-276	2
260	Response to crowded conditions reveals compact nucleus for amyloid formation of folded protein. 2021 , 2,	1
259	Probing Mechanisms and Therapeutic Potential of β -Secretase in Alzheimer's Disease. 2021 , 26,	3
258	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. 2021 , 34, 266-274	14

- 257 Effects of Ions and Small Compounds on the Structure of A β Monomers. **2021**, 125, 1085-1097 2
- 256 Preparation of Amyloid Fibrils Using Recombinant Technology. **2021**, 2347, 113-121
- 255 Lack of occlusal support did not impact amyloid β deposition in APP knock-in mice. **2021**, 1
- 254 Bioactive 3D structures of naturally occurring peptides and their application in drug design. **2021**, 85, 24-32 1
- 253 The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. **2021**, 22, 25
- 252 Remodeling Alzheimer-amyloidosis models by seeding. **2021**, 16, 8 0
- 251 Evaluating the Multifunctionality of a New Modulator of Zinc-Induced A β Aggregation Using a Novel Computational Approach. **2021**, 61, 1383-1401 2
- 250 The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. **2021**, 48, 2140-2156 31
- 249 Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease. **2021**, 108, 104681 20
- 248 Therapies for Alzheimer's disease: a metabolic perspective. **2021**, 132, 162-172 3
- 247 Platelets transport β amyloid from the peripheral blood into the brain by destroying the blood-brain barrier to accelerate the process of Alzheimer's disease in mouse models. **2021**, 13, 7644-7659 8
- 246 Recent advances in pre-clinical diagnosis of Alzheimer's disease. **2021**, 1
- 245 Amyloid- β differentially stimulates proliferation, activation of oxidative stress and inflammatory responses in male and female hippocampal astrocyte cultures. **2021**, 195, 111462 1
- 244 Live Cell FRET Imaging Reveals Amyloid β Peptide Oligomerization in Hippocampal Neurons. **2021**, 22, 2
- 243 A β -16 controls synaptic vesicle pools at excitatory synapses via cholinergic modulation of synapsin phosphorylation. **2021**, 78, 4973-4992 2
- 242 Supramolecular Antiparallel β Sheet Formation by Tetrapeptides Based on Amyloid Sequence. **2021**, 125, 4274-4285 2
- 241 Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. **2021**, 15, 630172 1
- 240 Amyloid-Mediated Mechanisms of Membrane Disruption. **2021**, 1, 137-156 1

239	Extracellular Hsp90 α Detoxifies β Amyloid Fibrils Through an NRF2 and Autophagy Dependent Pathway.	1
238	Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. 2021 , 19,	10
237	A β 3 aggregates exhibit enhanced prion-like seeding activity in mice. 2021 , 9, 83	3
236	Exploring the Impact of Glyoxal Glycation on β Amyloid Peptide (A β) Aggregation in Alzheimer's Disease. 2021 , 125, 5559-5571	2
235	Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid- β Peptide Associated with Alzheimer's Disease Development. 2021 , 26,	3
234	Contribution of astrocytes to neuropathology of neurodegenerative diseases. 2021 , 1758, 147291	16
233	The interplay between lipid and A β amyloid homeostasis in Alzheimer's Disease: risk factors and therapeutic opportunities. 2021 , 236, 105072	2
232	An evaluation of the self-assembly enhancing properties of cell-derived hexameric amyloid- β 2021 , 11, 11570	2
231	Is Cerebral Amyloid- β Deposition Related to Post-stroke Cognitive Impairment?. 2021 , 12, 946-957	5
230	Role of Withaferin A and Its Derivatives in the Management of Alzheimer's Disease: Recent Trends and Future Perspectives. 2021 , 26,	4
229	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. 2021 , 290, 583-601	15
228	Recapitulation of selective nuclear import and export with a perfectly repeated 12mer GLFG peptide. 2021 , 12, 4047	1
227	Nanomechanical Stability of A β Tetramers and Fibril-like Structures: Molecular Dynamics Simulations. 2021 , 125, 7628-7637	2
226	Assembly of β -secretase occurs through stable dimers after exit from the endoplasmic reticulum. 2021 , 220,	1
225	Sensitivity-Enhanced Solid-State NMR Detection of Structural Differences and Unique Polymorphs in Pico- to Nanomolar Amounts of Brain-Derived and Synthetic 42-Residue Amyloid- β Fibrils. 2021 , 143, 11462-11472	9
224	Tau/A β chimera peptides: A Thioflavin-T and MALDI-TOF study of A β amyloidosis in the presence of Cu(II) or Zn(II) ions and total lipid brain extract (TLBE) vesicles. 2021 , 237, 105085	1
223	Importance of Hydrogen Bonding: Structure-Activity Relationships of Ruthenium(III) Complexes with Pyridine-Based Ligands for Alzheimer's Disease Therapy. 2021 , 64, 10124-10138	3
222	Impairment of visual cortical plasticity by amyloid-beta species. 2021 , 154, 105344	1

221	Macromolecular crowding modulates β -synuclein amyloid fiber growth. 2021 , 120, 3374-3381	9
220	Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products. 2021 , 2021, 9982954	8
219	Postmortem Neocortical H-PiB Binding and Levels of Unmodified and Pyroglutamate A β n Down Syndrome and Sporadic Alzheimer's Disease. 2021 , 13, 728739	0
218	Neuronal Cell Cycle Re-Entry Enhances Neuropathological Features in AppNLF Knock-In Mice. 2021 , 82, 1683-1702	3
217	Flavonoids with Potential Anti-Amyloidogenic Effects as Therapeutic Drugs for Treating Alzheimer's Disease. 2021 , 84, 505-533	2
216	Mutations in the Amyloid- β Protein Precursor Reduce Mitochondrial Function and Alter Gene Expression Independent of 42-Residue Amyloid- β Peptide. 2021 , 83, 1039-1049	0
215	Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. 2021 , 10, 38	0
214	Solubility of A β 0 peptide. 2021 , 100024	1
213	Blood biomarkers for the diagnosis of amnesic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. 2021 , 128, 479-486	10
212	Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery. 2021 , 71, 101451	4
211	Impact of Au metal clusters on the structural and inhibitory mechanism of A β peptide: A theoretical approach. 2022 , 204, 111920	2
210	MicroRNA-138 Overexpression Alters A β 2 Levels and Behavior in Wildtype Mice. 2020 , 14, 591138	3
209	Suppression of aggregate and amyloid formation by a novel intrinsically disordered region in metazoan Hsp110 chaperones. 2021 , 296, 100567	4
208	Suppression of aggregate and amyloid formation by a novel intrinsically disordered region in metazoan Hsp110 chaperones.	
207	Protease Inhibitors and their Involvement in Neurological Disorders. 2007 , 591-624	2
206	Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A β 2-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD). 2007 , 167-193	1
205	Amyloid- β Interactions with Lipid Rafts in Biomimetic Systems: A Review of Laboratory Methods. 2021 , 2187, 47-86	3
204	Endosome-lysosomes, ubiquitin and neurodegeneration. 1996 , 389, 261-9	38

203	Amyloid-Beta, BDNF, and the Mechanism of Neurodegeneration in Alzheimer's Disease. 2014 , 1597-1620	2
202	Familial Amyotrophic Lateral Sclerosis and Alzheimer's Disease. 1998 , 145-159	6
201	Molecular Pathology of Alzheimer's Disease and Related Disorders. 1999 , 603-654	18
200	Cerebral Zinc Metabolism in Alzheimer's Disease. 1997 , 225-237	2
199	Amyloid-Derived Free Radical Oxidation. 1997 , 145-167	3
198	Analysis of Abeta interactions using ProteinChip technology. 2008 , 494, 71-86	2
197	Amyloid Peptide neurotoxicity assay using cultured rat cortical neurons. 2012 , 846, 57-65	4
196	Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. 2019 , 1201, 275-353	4
195	Proteolytic Processing of the Amyloid Precursor Protein of Alzheimer's Disease. 2000 , 359-374	2
194	The APP and PS1/2 Mutations Linked to Early Onset Familial Alzheimer's Disease Increase the Extracellular Concentration of Aβ ₄₂ (43). 1998 , 27-33	1
193	Alzheimer's Disease and Hemorrhagic Stroke: Their Relationship to Aβ ₄₂ Amyloid Deposition. 1995 , 37-48	3
192	Amyloid in Alzheimer's Disease and Animal Models. 1994 , 156-168	1
191	The Role of Synuclein in Parkinson's Disease: A Biophysical Analogy to Aβ and Alzheimer's Disease. 2000 , 1-9	1
190	Preparation and Structural Characterization of Pre-fibrillar Assemblies of Amyloidogenic Proteins. 2012 , 61-102	1
189	Degeneration of Human Cerebrovascular Smooth Muscle Cells and Pericytes Caused by Amyloid β Protein. 2000 , 265-279	3
188	Cerebral Amyloid Angiopathy. 2004 , 693-705	4
187	Application of yeast to studying amyloid and prion diseases. 2020 , 105, 293-380	6
186	The hazardous effects of the environmental toxic gases on amyloid beta-peptide aggregation: A theoretical perspective. 2020 , 263, 106394	12

185	Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues.. 1994 , 269, 10205-10208	121
184	The Alzheimer A beta peptide develops protease resistance in association with its polymerization into fibrils.. 1994 , 269, 30773-30776	70
183	Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure.. 1994 , 269, 24290-24297	389
182	Surfactant properties of Alzheimer's A beta peptides and the mechanism of amyloid aggregation.. 1994 , 269, 28551-28554	206
181	APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. 1994 , 269, 32721-32724	119
180	Research Advances in the Biology of Alzheimer's Disease. 1994 , 10, 249-255	3
179	Kidney and liver involvement in monoclonal light chain disorders. 2002 , 22, 319-330	73
178	Physiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis. 2003 , 2003, re4-re4	2
177	Alzheimer disease therapy: Can the amyloid cascade be halted?. 2003 , 111, 11-18	116
176	Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. 2006 , 116, 193-201	155
175	Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. 1996 , 109, 999-1008	93
174	Aβ0 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. 2010 , 5, e15725	82
173	Alzheimer's disease-linked mutations in presenilin-1 result in a drastic loss of activity in purified γ-secretase complexes. 2012 , 7, e35133	51
172	Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. 2013 , 8, e66381	93
171	Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. 1998 , 18, 3213-23	217
170	Sleep and Alzheimer's Disease. 2015 , 6, 1-9	2
169	Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation. 2019 , 20, 1680-1694	4
168	Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. 2013 , 10, 1057-69	65

167	CSF tau and β amyloid as biomarkers for mild cognitive impairment. 2004 , 6, 379-90	16
166	Elevated age-related cortical iron, ferritin and amyloid plaques in APP(swe)/PS1(deltaE9) transgenic mouse model of Alzheimer's disease. 2019 , 68, S445-S451	9
165	Zn Interaction with Amyloid- β Affinity and Speciation. 2019 , 24,	6
164	The complexities underlying age-related macular degeneration: could amyloid beta play an important role?. 2017 , 12, 538-548	25
163	Pharmacological Assessment of β -Secretase Activity from Rodent and Human Brain. 2012 , 03, 149-161	3
162	Control of Morphology and Subsequent Toxicity of A β Amyloid Fibrils through the Dequalinium-induced Seed Modification. 2007 , 28, 2283-2287	2
161	Synthesis of Thia(oxa)zopyridines and Their Inhibitory Activities for β Amyloid Fibrillization. 2008 , 29, 2331-2336	8
160	Synthesis of Functionalized Benzoxazoles and Their Binding Affinities to A β 2 Fibrils. 2008 , 29, 1765-1768	2
159	Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. 2011 , 1, 8-18	27
158	Mechanism of Cellular Formation and In Vivo Seeding Effects of Hexameric β Amyloid Assemblies. 2021 , 58, 6647-6669	0
157	Prolonged Volatile Anesthetic Exposure Exacerbates Cognitive Impairment and Neuropathology in the 5xFAD Mouse Model of Alzheimer's Disease. 2021 ,	1
156	Cryo-EM Structures of Amyloid- β 2 Filaments from Human Brain.	1
155	The Amyloid Fibril-Forming β Sheet Regions of Amyloid β and β Synuclein Preferentially Interact with the Molecular Chaperone 14-3-3 σ . 2021 , 26,	2
154	Interactions of the A β (1-42) Peptide with Boron Nitride Nanoparticles of Varying Curvature in an Aqueous Medium: Different Pathways to Inhibit β Sheet Formation. 2021 , 125, 11159-11178	3
153	Presenilins and β Amyloid Precursor Protein-Proteolytically Processed Proteins Involved in the Generation of Alzheimer's β Amyloid β Peptide. 2000 , 375-395	
152	The Pathophysiology of Alzheimer's Disease. 2000 , 83-104	1
151	Amyloid β Protein Internalization and Production by Canine Smooth Muscle Cells. 2000 , 251-264	
150	Clinical and Genetic Aspects of Hereditary Cerebral Hemorrhage with Amyloidosis Dutch Type (HCHW A-D). 2000 , 103-119	1

- 149 Role of presenilin in APP processing and A β production. **2001**, 183-191
- 148 Proinflammatory actions of derivatives of the β amyloid precursor protein. **2001**, 155-172
- 147 REFERENCES. **2002**, 195-250
- 146 Pathological Detection of AB and APP in Brain. **2004**,
- 145 Instabilities of proteins: theoretical aspects, degradation products and methods for their detection. **2005**, 51, 3-8
- 144 Methionine Sulfoxide Reductase System. **2005**, 199-212
- 143 β Secretase as a Target for Alzheimer's Disease. **2007**, 125-140
- 142 A β Variants and Their Impact on Amyloid Formation and Alzheimer's Disease Progression. **2007**, 102-124
- 141 Beta-amyloid precursor protein and early-onset Alzheimer's disease. **1996**, 199, 170-80
- 140 Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy. **1996**, 199, 73-81; discussion 81-9 3
- 139 Metabolic Abnormalities in Alzheimer Disease. **2009**, 483-530
- 138 Presenilin-Based Transgenic Models of Alzheimer's Dementia. **2011**, 415-437
- 137 Mouse Models of Alzheimer's Disease. **2010**, 252-256
- 136 Neuropathology and Iron: Central Nervous System Iron Homeostasis. **2012**, 455-476
- 135 Pathogenesis of Alzheimer's Disease with Special Reference to Amyloid β Protein. **2012**, 8, 285-290
- 134 The Amyloid β -Protein and Alzheimer's Disease. **2012**, 1-85
- 133 Emerging Principles and Biomarkers in In Vitro Diagnostics for Alzheimer's Disease. **2012**, 87-102
- 132 Controlling Reversible Self-Assembly Path of Amyloid Beta Peptide over Gold Colloidal Nanoparticles Surfaces. **2013**, 279-304 1

- 131 Protein seeding in Alzheimer's disease and Parkinson's disease: Similarities and differences. **2014**, 4, 23
- 130 Rapid, large-scale synthesis and solubility studies of the amyloid β protein of Alzheimer's disease. **1994**, 502-504
- 129 Synthesis and aggregation of C-terminal analogs of β amyloid. **1994**, 511-513
- 128 Genetic Defects in Early Onset Alzheimer's Disease and Related Disorders. **1994**, 199-208
- 127 Processing of the amyloid β protein precursor. **1995**, 115-143 1
- 126 Cellular and animal models of amyloid β protein amyloidosis. **1995**, 183-192
- 125 In Vivo Biology of Amyloid Precursor Protein/Amyloid Precursor-like Proteins and Transgenic Animal Models of Alzheimer's Disease. **1996**, 61-76
- 124 Pathological Changes in the Elderly Human Brain. **1997**, 5-114
- 123 Alzheimer's Disease: A Matter of Dominance. **1998**, 11-18
- 122 Alzheimer's Disease and Genetically Engineered Animal Models. **1999**, 187-214
- 121 The Molecular Mechanism of Amyloidosis in Alzheimer's Disease. **1999**, 1
- 120 Impairment of Energy Metabolism and Vascular Function in Alzheimer's Disease. **2015**, 219-238
- 119 Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351
- 118 Verubecestat. **2017**, 204-251
- 117 The unique nested gene ALZAS as a potential source of A β peptides in Alzheimer's disease.
- 116 Misfolded amyloid β 2 induced impairment of the endosomal-lysosomal pathway revealed by real-time optical monitoring.
- 115 Elucidating the molecular determinants of A β aggregation with deep mutational scanning.
- 114 The inhibition of cellular toxicity of amyloid-beta by dissociated transthyretin.

- 113 Amyloid β peptide interaction with GM1 containing model membrane. **2020**, 32, 1-24
- 112 Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer's disease. 2
- 111 Microbiota-Derived β Amyloid-like Peptides Trigger Alzheimer's Disease-Related Pathways in the SH-SY5Y Neural Cell Line. **2021**, 13, 0
- 110 Cell-derived hexameric β amyloid: a novel insight into composition, self-assembly and nucleating properties.
- 109 Molecular Dynamics Simulations of Acetylcholinesterase β Amyloid Peptide Complex. **2020**, 20, 140-154
- 108 Mechanism of cellular production and in vivo seeding effects of hexameric β amyloid assemblies.
- 107 Reconstruction of Alzheimer's Disease Cell Model via Extracted Peripheral Blood Molecular Cells from a Sporadic Patient. **2020**, 2020, 8897494 1
- 106 CHAPTER 5: Peptide Self-assembly Applied to Catalytic Asymmetric Aldol Reactions. **2020**, 126-173 0
- 105 Genomics of Alzheimer's disease. **2020**, 3-18
- 104 Association between Sleep, Alzheimer's, and Parkinson's Disease. **2021**, 10, 0
- 103 Alzheimer disease therapy: can the amyloid cascade be halted?. **2003**, 111, 11-8 42
- 102 Neurotoxicity of the Alzheimer's β Amyloid Peptide. **2005**, 61-74
- 101 Cortical Cholinergic Deafferentation Induces A β Deposition. **2005**, 143-180
- 100 Mouse Model for Alzheimer's Disease. **2008**, 191-199
- 99 Physiologic and Neurotoxic Properties of A β Peptides. **2007**, 179-197
- 98 Cerebrospinal fluid protein biomarkers for Alzheimer's disease. **2004**, 1, 213-225
- 97 Biomarkers of Alzheimer disease in plasma. **2004**, 1, 226-234
- 96 Single cell gene expression profiling in Alzheimer's disease. **2006**, 3, 302-318

95	[The future of dementia prevention and treatment strategies]. 2020 , 57, 374-396	
94	Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. 1999 , 340 (Pt 3), 703-9	19
93	Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of beta-amyloid peptide. 2000 , 348 Pt 1, 137-44	42
92	Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. 1997 , 150, 2181-95	252
91	Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. 1996 , 148, 1257-66	135
90	Amyloid beta protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance of A beta 42(43) and association of A beta 40 with cored plaques. 1996 , 148, 259-65	87
89	Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques. 1996 , 148, 1749-56	19
88	P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. 1996 , 149, 585-96	46
87	Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. 1994 , 144, 1082-8	37
86	Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopathy cases. 1997 , 3, 695-707	46
85	The amyloid beta ion channel hypothesis of Alzheimer's disease. 2007 , 3, 597-612	51
84	Catastrophe, chaos and Alzheimer's disease. The F E Williams Lecture. 1995 , 29, 412-8	3
83	Structural biology of cell surface receptors implicated in Alzheimer's disease.. 2022 , 14, 233-255	0
82	An insight into Alzheimer's disease and its on-setting novel genes. 2021 , 57,	2
81	The role of trimethylamine-N-Oxide in the development of Alzheimer's disease. 2021 ,	2
80	Biological and methodological complexities of beta-amyloid peptide: Implications for Alzheimer's disease research. 2021 ,	2
79	The Neurochemistry of Alzheimer's Disease: One of the Most Common Causes of Reduced Capability in the Adult Population. 2022 , 81-93	
78	Synaptic dysfunction in early phases of Alzheimer's Disease.. 2022 , 184, 417-438	2

77	Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways.. 2022 , 40, 298-318	0
76	Cryo-EM structures of amyloid- β 2 filaments from human brains.. 2022 , 375, 167-172	27
75	Relationship between Cognitive Dysfunction and Age-Related Variability in Oxidative Markers in Isolated Mitochondria of Alzheimer's Disease Transgenic Mouse Brains.. 2022 , 10,	0
74	Implication of Adult Hippocampal Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches.. 2022 , 11,	1
73	Turning the tide on Alzheimer's disease: modulation of β -secretase.. 2022 , 12, 2	3
72	Kinetic Modulation of Amyloid- β (1-42) Aggregation and Toxicity by Structure-Based Rational Design.. 2022 ,	0
71	Dual-Emission GFP Chromophore-Based Derivative for Imaging and Discriminating A β Oligomers and Aggregates.. 2022 ,	2
70	Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseases.. 2021 , 101478	4
69	The Emergence of Model Systems to Investigate the Link Between Traumatic Brain Injury and Alzheimer's Disease.. 2021 , 13, 813544	0
68	All-Atom Molecular Dynamics Simulation Methods for the Aggregation of Protein and Peptides: Replica Exchange/Permutation and Nonequilibrium Simulations.. 2022 , 2340, 197-220	0
67	Optogenetics: implications for Alzheimer's disease research and therapy.. 2022 , 15, 20	1
66	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice.. 2022 , 23,	1
65	Stability Enhancement of a β Stacked Helical Structure Using Substituents of an Amino Acid Side Chain: Helix Formation via a Nucleation-Elongation Mechanism.. 2022 ,	2
64	Alzheimer's disease - the journey of a healthy brain into organ failure.. 2022 , 17, 18	3
63	Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition.. 2022 , 86, 1025-1035	0
62	Kinetics of amyloid accumulation in physiological viscosity.. 2022 , 214, 112449	
61	The Impact of Medium Chain and Polyunsaturated ω -Fatty Acids on Amyloid- β Deposition, Oxidative Stress and Metabolic Dysfunction Associated with Alzheimer's Disease.. 2021 , 10,	4
60	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. 2021 , 12, 7112	2

59	Molecular Dynamics Simulation Studies on the Aggregation of Amyloid- β Peptides and Their Disaggregation by Ultrasonic Wave and Infrared Laser Irradiation.. 2022 , 27,	0
58	Data_Sheet_1.ZIP. 2020 ,	
57	Data_Sheet_2.PDF. 2020 ,	
56	Image_1.TIF. 2020 ,	
55	Image_2.TIF. 2020 ,	
54	Image_3.TIF. 2020 ,	
53	Image_4.TIF. 2020 ,	
52	Data_Sheet_1.pdf. 2018 ,	
51	Presenilin/ γ -Secretase in the Pathogenesis of Alzheimer's Disease. 2022 , 325-334	
50	Screening neuroprotective compounds in herpes-induced Alzheimer's disease cell and 3D tissue models.. 2022 ,	
49	Constructing conformational library for amyloid- β dimers as the smallest toxic oligomers using two CHARMM force fields.. 2022 , 115, 108207	1
48	Amyloid- β Oligomers: Multiple Moving Targets. 2022 , 2, 91-110	2
47	Effects of Familial Alzheimer's Disease Mutations on the Folding Free Energy and Dipole-Dipole Interactions of the Amyloid β Peptide.	
46	The role of short-chain fatty acids in central nervous system diseases.	2
45	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers.	1
44	Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease. 16,	1
43	Intraneuronal β Amyloid Accumulation: Aging HIV-1 Human and HIV-1 Transgenic Rat Brain. 2022 , 14, 1268	0
42	Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. 16,	0

41	Mouse Models of Alzheimer's Disease. 15,	1
40	Computational insight into the binding of bryostatin 1 with ferritin: implication of natural compounds in Alzheimer's disease therapeutics. 1-11	
39	Amyloid precursor protein (APP) and amyloid β interact with cell adhesion molecules: Implications in Alzheimer's disease and normal physiology. 10,	0
38	New Insights into the Molecular Interplay between Human Herpesviruses and Alzheimer's Disease: A Narrative Review. 2022, 12, 1010	0
37	A β 2 oligomers can seed the fibrillization of A β 40 peptides.	
36	Enhancing the Amyloid- β Anti-Aggregation Properties of Curcumin via Arene-Ruthenium(II) Derivatization. 2022, 23, 8710	2
35	Synthesis and Characterization of Propeller- and Parallel-Type Full-Length Amyloid β 0 Trimer Models. 2022, 13, 2517-2528	1
34	Biomarkers in cerebrospinal fluid and blood aid diagnosis of dementia. 2023, 47-68	0
33	Molecular linkages among A β tau, impaired mitophagy, and mitochondrial dysfunction in Alzheimer's disease. 2022, 91-109	0
32	Basics of amyloid β protein in Alzheimer's disease. 2022, 73-89	0
31	Optimization of the Linker Length in the Dimer Model of E22P-A β 0 Tethered at Position 38. 2022, 13, 2913-2923	0
30	A Review of Application of A β 2/40 Ratio in Diagnosis and Prognosis of Alzheimer's Disease. 2022, 1-18	1
29	Effects of Familial Alzheimer's Disease Mutations on the Folding Free Energy and Dipole-Dipole Interactions of the Amyloid β Peptide. 2022, 126, 7552-7566	0
28	Covalent fragment inhibits intramembrane proteolysis. 9,	0
27	Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets. 2022, 14, 8077-8094	0
26	Perivascular spaces as a potential biomarker of Alzheimer's disease. 16,	0
25	Key Residue for Aggregation of Amyloid- β Peptides.	0
24	How Do Salt and Lipids Affect Conformational Dynamics of A β 42 Monomers in Water?.	0

23	Cerebral Superficial Siderosis.	0
22	Simple, Reliable Protocol for High-Yield Solubilization of Seedless Amyloid- β Monomer.	0
21	Putative Structures of Membrane-Embedded Amyloid β Oligomers.	1
20	Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of A β 24-induced Alzheimer's disease rat model.	0
19	Structurally Altered, Not Wild-Type, Pentameric C-Reactive Protein Inhibits Formation of Amyloid- β Fibrils. 2022 , 209, 1180-1188	1
18	The Molecular Mechanism of Amyloid Formation in Alzheimer's Disease. 1995 , 30, 621s-633s	0
17	Decreased cerebrospinal fluid A β 8, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy.	0
16	Post-Translational Chemical Modification of Amyloid- β Peptides by 4-Hydroxy-2-Nonenal. 2023 , 92, 499-511	0
15	The interaction of peptide inhibitors and A β protein: Binding mode analysis, inhibition of the formation of A β aggregates, and then exert neuroprotective effects. 15,	0
14	Super-resolution fluorescence microscopic imaging in pathogenesis and drug treatment of neurological disease. 2023 , 196, 114791	0
13	Plantainoside B in <i>Bacopa monniera</i> ; Binds to A β Aggregates Attenuating Neuronal Damage and Memory Deficits Induced by A β 2023 , 46, 320-333	0
12	The Curcumin Derivative GT863 Protects Cell Membranes in Cytotoxicity by A β Oligomers. 2023 , 24, 3089	0
11	Amyloid Fibers of β Synuclein Catalyze Chemical Reactions. 2023 , 14, 603-608	0
10	Congo Red-Derived Carbon Dots: Simultaneously as Fluorescence Probe for Protein Aggregates, Inhibitor for Protein Aggregation, and Scavenger of Free Radicals. 2205634	0
9	Stability of the A β 2 Peptide in Mixed Solutions of Denaturants and Proline. 2023 , 127, 1572-1585	0
8	Intracellular Amyloid- β in the Normal Rat Brain and Human Subjects.	0
7	The Pathological Effects of Circulating Hydrophobic Bile Acids in Alzheimer's Disease. 2023 , 7, 173-211	0
6	Endosome and Lysosome Membrane Properties Functionally Link to β -Secretase in Live/Intact Cells. 2023 , 23, 2651	0

- 5 Decoding the Roles of Amyloid- β Key Oligomerization Domains toward Designing Epitope-Specific Aggregation Inhibitors. ○
- 4 β -Carotene, a Potent Amyloid Aggregation Inhibitor, Promotes Disordered A β Fibrillar Structure. **2023**, 24, 5175 ○
- 3 Energy landscapes of A β monomers are sculpted in accordance with Ostwald's rule of stages. **2023**, 9, ○
- 2 A new class of monoclonal A β antibodies selectively targets and triggers deposition of A β protofibrils. ○
- 1 Metals in Alzheimer's Disease. **2023**, 11, 1161 ○